JOURNAL TRANSCRIPT

---

Curriculum Vitae

Paul Mainwaring

Associate Professor University of Queensland

Consultant Medical Oncologist iCON Cancer Care

Table of Contents General Information ................................................................................................... 3 Medical Employment & Training History: ................................................................ 4 General Medical Training ...................................................................................... 4 Medical Oncology Training: Australia ............................................................... 5 Medical Oncology Training: United Kingdom ................................................... 5 Lymphoma Unit ..................................................................................................... 5 October 1999 – November 2002 ................................................................................ 6 January 2003 - June 2010 ......................................................................................... 6 July 2010 - Present .................................................................................................... 6 Laboratory Research Experience ........................................................................... 7 Current Laboratory Experience............................................................................... 7 Teaching Experience .................................................................................................. 8 Management Activities .............................................................................................. 8 Interests ...................................................................................................................... 9 Academic Activities ................................................................................................... 9 Publications .............................................................................................................. 10 Published peer review .................................................................................... 10-19 Book Chapters ...................................................................................................... 20 MD Thesis ...................................................................................................... 20 Published Abstracts ........................................................................................ 21-30 Oral Presentations ................................................................................................ 31 Talks and Presentations.......................................................................................... 32-49

Paul Mainwaring

General Information Name: Home Address:

Paul Norman Mainwaring 3 Eblin Drive Hamilton 4007 Queensland Australia

Professional

Consultant Medical Oncologist

Address

iCon Cancer Care Level 5, Mater Medical Centre 293 Vulture Street South Brisbane 4101 QLD Australia Ph +61 7 3737 4500 Fax +61 7 3737 4701 [email protected] Canossa Private Hospital Seventeen Mile Rocks Rd Oxley 4075 Ph + 61 737375520 Fax +61 737175649

Date Of Birth:

19th July 1965

Marital Status:

Married, two children

Secondary Education

Knox Grammar School 1977-82 HSC 447 top 1%

Medical School:

University of Sydney, Faculty of Medicine 1983- 1988

Qualifications:

M.B.B.S. University of Sydney, 1988 F.R.A.C.P. 1992 M.D. University of London New South Wales, Australia No. 247 334 Queensland, Australia No. 1024352 United Kingdom GMC No. 4148230 Medical Oncology Australia May 1995 UK CCST -May 1999

Medical Registration: Accreditation Affiliations

Grants Awarded

Medical Oncology Group, Australia Clinical Oncology Society of Australia Royal Australasian College of Physicians Association of Cancer Physicians British Association of Cancer Research American Society of Clinical Oncology European Society of Medical Oncology US Army Materials and Research Command Breast Cancer Research Program Grant 1997.US$300 000

3

Paul Mainwaring

Medical Employment & Training History: Current Position Consultant Medical Oncologist Haematology & Oncology Clinics of Australia Consultant Medical Oncologist Canossa Private Hospital

General Medical Training 1989-1992 Royal Prince Alfred Hospital, Sydney, Australia 1989 Houseman January - March March - May May - July August - October October - December

Accident & Emergency Thoracic medicine Orthopaedics Vascular surgery Floating rotation

1990 January - March March - May May - July August - October October - December

Senior Houseman Cardiology Nephrology Endocrinology Intensive care Accident & Emergency

1991 January - March April - June July - September October - December

Medical Registrar

1992

Medical Registrar

January - April May - June

Medical Oncology Gastroenterology Accident & Emergency Drug & Alcohol

Rheumatology Neurology

4

Paul Mainwaring

Medical Oncology Training:

Australia

1992 - 1994

Royal Prince Alfred Hospital, Sydney, Australia

1992 July – December

Snr. Registrar Haematology Prof. P. Vincent

1993-4 January – October November – June

Snr. Registrar Medical Oncology Prof. M. Tattersall, Dr. J. Grygiel Prof. A. Coates, Prof. J. Simes

1994 July – December

The Royal North Shore Hospital, Sydney, Australia Dr M Holocheck

Medical Oncology Training:

Radiation Oncology Registrar

United Kingdom

The Royal Marsden NHS Trust, London. January - September

Clinical Research Fellow Dr M Gore

Gynaecology, Skin, Renal Head and Neck Units

September 1995 - September 1997

Clinical Research Fellow Dr. I.E. Smith

Breast and Lung Units

September 1997 - March 1998 March 1998 - October 1998 September 1997 - March 1998 March 1998 - October 1998

Gastrointestinal Unit Dr D Cunningham Lymphoma Unit Sarcoma and Clinical Pharmacology Unit Dr I Judson Prof. R Powles Leukaemia and Myeloma Units Testicular Tumour Clinic Prof. A Horwich

November 1998 – October 1999

Specialist Registrar Breast Unit Prof. T Powles

5

Paul Mainwaring

October 1999 – November 2002 NHS consultant position, Guy’s, King’s & St. Thomas’ Joint Cancer Centre with sub-speciality interests in gastro-intestinal malignancies and lymphomas. I have conjointly established a multidisciplinary team comprising medical, clinical, palliative and surgical oncologists, clinical, chemotherapy and research nurse specialists at GKTJCC in these sub-disciplines. Positions: NHS Information Authority National Minimum Dataset Committee South East London Cancer Task Force Colorectal and Information Subcommittees St Thomas Drug’s and Therapeutics Committee South Thames Haematology Register – Lymphoma representative GKTJCC Cancer management committee

January 2003 Director, Medical Oncology, Mater Health Services, Brisbane Director, Medical Oncology Research Co-developed electronic early referral system Established formal multi-disciplinary led clinical care Established formal multi-disciplinary clinics Developed clinical research team in solid tumours; interaction with HREC Developed translational research team Reconfigure outpatient, day oncology unit care Lead acquisition electronic prescribing system from proforma system

January 2004 Visiting Consultant Medical Oncologist Haematology & Oncology Clinics of Australasia 293 Vulture St South Brisbane Chermside Medical Centre, Chermside, Brisbane Wesley Hospital, Auchenflower, Brisbane Mater Hospital, Gladstone Townsville Hospital, Townsville Wesley Hospital, Townsville Ipswich Hospital, Ipswich

2007 – June 2010 Senior Principal Clinical Research Investigator Mater Medical Research Institute Raymond Terrace South Brisbane 4101 Queensland Australia

July 2010- Present Constant Medical Oncologist Senior Principal Clinical Research Investigator iCON Cancer Care (formerly known as Haematology & Oncology Clinics of Australia) Level 5, Mater Medical Centre 293 Vulture Street South Brisbane 4101 Queensland Australia

6

Paul Mainwaring

Laboratory Research Experience 1992 Snr. Registrar Haematology July – December Prof. P. Vincent During this interval I spent 2 sessions per week in the laboratory learning to culture leukaemic cells, identify new haematological CD antigens and compare automated cytogenetic analysis with standard microscopic techniques. September 1995 - August 1997 Proliferation, Apoptosis And Control Of Apoptosis In The Endocrine Management Of Human Breast Cancer

MD in Medical Oncology Prof. M Dowsett, Supervisor Dept. Academic Biochemistry The Institute of Cancer Research

My research interests have always been the use of human biological samples to explore the effects of treatment on disease response. My laboratory research at the ICR was a translational project exploring the relationship between members of the Bcl-2 family, apoptosis and proliferation in human carcinomas and cell lines. These relationships were examined before, during and after antitumour therapy comparing responsive and resistant tumours. The in vitro work involved exploring different techniques to measure apoptotic cells and used Western and Northern blotting to investigate in vitro relationships. I developed immunohistochemical techniques using new antibodies generated at The Burnham Institute, La Jolla for use on paraffin-embedded and frozen tissues, collected in an ongoing basis from patients enrolled in clinical trials at the Royal Marsden, augmenting a large and carefully constructed human tumour bank. The resulting thesis has been submitted to The University of London. Several papers resulting from this work are ready for submission, with one paper published. US Army Grant I was fortunate enough to be involved in a collaborative study with dedicated flow cytometric experts to adapt the immunohistochemical detection of strand breakages of apoptotic cells to flow cytometric analysis, such that an apoptotic index could be generated from fine-needle aspirates of human tumours. This lead to a successful application to the US Army Material and Research Command for further funding to validate this new technique in vivo. I thoroughly enjoyed working in the laboratory of Professor Dowsett and learning the discipline of scientific method. I see translational research as an essential component of a modern academic oncology practice and will always be grateful for the opportunities presented whilst working in this laboratory. Current Laboratory Research Since completing my MD I have maintained my interest in translational research. I am currently involved in translational programs using biologically based tumour samples in conjunction with genomics technology to measure changes in gene, mRNA and protein expression with therapy. In association with this program is the development of the bioinformatics necessary to interpret these changes.

7

Paul Mainwaring

Teaching Experience Throughout my medical career, I have been responsible for co-ordinating undergraduate, resident and registrar clinical training. I am keen to continue the tradition of clinical teaching at the bedside, combining it with newer graphical presentation techniques to enhance the learning experience. Whilst at Royal Prince Alfred Hospital, I served as the junior medical officer representative on the hospital board and was actively involved in preparation for the F.R.A.C.P clinical examinations, both in preparing applicants as well as arranging suitable patients for the examination. Whilst at The Royal Marsden Hospital, I was involved in conducting clinical courses for the senior house officers taking their M.R.C.P. examinations. I have been responsible for conducting teaching sessions and delivering lectures on a range of malignancies, both within The Royal Marsden NHS Trust to medical and nursing personnel, and to the pharmaceutical industry and held the position of Associate College Tutor for the Sutton branch of The Royal Marsden NHS Trust.

In Australia I have been involved in undergraduate and post graduate teaching and established a weekly teaching program through both the University of Queensland and Bond University.

Management Activities An ever-present component of my clinical duties has been the organisation and conduct of clinical audits, morbidity and mortality meetings, grand round presentations, multidisciplinary clinical review meetings, journal clubs and conference presentations. During my training, I have been involved in attending unit business and management meetings, assessing drug budgets and preparing business cases for the introduction of new therapies into the clinic. Keele University; Residential Management Course for SpRs, April 1999 I participated in an NHS sponsored, 3-day resident management course for Specialist Registrars preparing for consultant practice. As a result of this experience I have an improved understanding of the recent changes in approach to health within the NHS, including implementation of the CalmanHine recommendations, implications of primary care groups and the changing role of health authorities, OATs negotiations and the role of the new evidence-based medical bodies, NICE and CHI. Management of clinical, preparation of clinical budgets, trust fund management, amongst other issues was vigorously discussed. I have a keen interest in the role of clinical databases, not only as a source of information for clinical trials, but also as a source of information for clinical audit, external peer review and incorporation into health economics analysis of the impact of cancer therapy and its' costs, something I see as vital to the future of clinical governance within an institution.

8

Paul Mainwaring

Interests During 1987-1988, I was selected from 17000 applicants as one of 12 Australian crewmembers for the delivery voyage of Britain's gift to the Australian people for the Australian Bicentenary, the tall ship, Young Endeavour.

Academic Activities For 2 years, whilst research fellow to Dr Smith, I co-ordinated and conducted the weekly multidisciplinary meeting. I was responsible for identifying and inviting regional, national and international speakers to lecture on a variety of clinical and research topics, often at short notice. This was invaluable experience in identifying innovative contributors to cancer care and in co-opting them to lecture to the Unit. I have lectured on the London Oncology SpR course, ICR and RMH Seminar Course in Oncology, MSc Course at King’s College and to nursing and allied staff as well as the pharmaceutical industry on a broad range of cancer and palliative care topics. I have participated in clinical audit with submissions to scientific and ethics committees As Director of Medical Oncology at Mater Health Services my portfolio included managing the weekly academic meeting and supervising general and medical oncology specialist trainees

9

Paul Mainwaring

Publications Published peer review 1.

Peter Schmid, Sarah E. Pinder, Duncan WheatleyJane Macaskill, Charles Zammit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwan Hadad, Alice Shia, Shah-Jalal Sarker, Louse Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Mark R. Lackner, Mika Derynck, Timothy R. Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alistair Thompson. Phase II Randomised Preoperative Window-of – Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone In Patients With Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology. Volume 34, Number 17, June 10, 2016. Published online ahead of print at www.jco.org on March 14, 2016. Doi:10.1200/JCO.2015.63.9179

2.

Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae Lyun Lee, Daniel Y. C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N.Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Giseal Schwab, Thomas E. Hutson, Sumanta Pal, Robert J. Motzer, for the METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results From A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology-D-16-00374. http://dx.doi.org/10.1016/ S14702045(16)30107-3. Embargo: June 5, 2016-16:12 (BST)

3.

Robert A Gardiner, Paul Mainwaring, Martin E Lavin. Integrating Molecular Profiling of Liquid Biopsy Samples With A Calculator Algorithm To Detect High-Risk Prostate Cancer. European Urology. (European Association of Urology). http://dx.doi.org/10.1016/j.eururo.2016.05.12

4.

D. Cella, B. Escudier, N.M Tannir, T. Powles, F. Donskov, K. Peltola, M. Schmidinger, D.Y.C. Heng, P.N. Mainwaring, H. Hammers, J.L Lee, B.I. Rini, B.J. Roth, J. Baer, M. Mangeshkar, C. Scheffold, T.E. Hutson, S. Pal, R.J. Motzer, T.K. Choueiri. Quality of Life (QoL) in the Phase 3 METEOR Trial of Cabozantinib vs Everolimus for Advanced Renal Cell Carcinoma. (RCC). ESMO (European Society for Medical Oncology, Copenhagen (Denmark), 7-11 Oct. 2016

5.

Simon J. Harrison, Paul Mainwaring, Timothy Price, Michael J. Millward, Peeter Padrik, Craig R. Underhill, Paul K. Cannell, Steven D. Reich, Mohit Trikha, Andrew Spencer. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052 Final Results. Manuscript Published Online April 26, 2016; DOI: 10.1158/1078-0432. Clinical Cancer Research-15-2616

6.

Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta Pal, Robert J. Motzer for the MMETEOR Investigators. Overall Survival Results from a Randomised Phase 3 Trial Comparing Cabozantinib and Everolimus in Advanced Renal Cell Carcinoma. 11 April 2016. The Lancet Oncology

7.

M. Schuler, J.C.-H. Yank, K. Park, J.H. Kim, J. Bennouna, Y.-M. Cheng, C. Chouaid, F. De Marinis, J.-F. Feng, F. Grossi, D.-W. Kim. X. Liu, S. Lu, J. Strausz, Y. Vinnyk, R. Wiewrodt, C. Zhou, B. Wang, V.K. Chand, D. Planchard for the LUX Lung 5 Investigators. Afatinib Beyond Progression in Patients With Non-Small-Cell Lung Cancer Following Chemotherapy, Erlotinib/Gefitinib and Afatinib: Phase III Randomized LUX-Lung 5 Trial. Annals of Oncology 27: 417-423, 2016. doi:10.1093/annonc/mdv597. Published online 8 December 2015

8.

E.G. Chiorean, D.D. Von Hoff, M. Reni, F.P. Arena, J.R. Infante, V.G. Bathini, T.E. Wood, P.N. Mainwaring, R.T. Muldoon, P.R. Clingan, V. Kunzmann, R.K. Ramanathan, J. Tabernero, D. Goldstein, D. McGovern, B. Lu, A. Ko. CA19-9 Decrease at 8 Weeks as a Predictor of Overall Survival in a Randomized Phase III Trial (MPACT) of Weekly Nab-Palitaxel Plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer. Annals of Oncology Advance Access published January 22, 2016 and March 2, 2016. Annals of Oncology 00: 1-7, 2016. Doi:10. 1093/annonc/mdw006

10

Paul Mainwaring

9.

Smith MR, de Bono JS, Sternberg CN, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman AM, Holzer W, De Wit R, Bogemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houede N, Hussain Syed, Lamb E, Polikoff J, Stenzi A, Mainwaring P, Ramies DA, Hessel C, Weitzman AL, Fizaz K. Phase 3 Study of Cabozantinib in Previously Treated Metastatic Castration-Resistnt Prostate Cancer (COMET-1). Last Modified 27 Aug. 2015 Journal of Clinical Oncology

10. Saad F., Shore N., Van Poppel H., Rathkopf D.E., Smith M.R., de Bono J.S., Logothetis C.J., de Souza P., Fizazi K., Mulders P.F., Mainwaring P., Hainsworth J.D., Beer T.M., North S., Fradet Y., Griffin T.A., De Porre P., Londhe A., Kheoh T., Small E.J., Scher H.I., Molina A., Ryan C.J. Impact of Bone-Targeted Therapies in Chemotherapy-Naïve Metastatic Castration-Resistance Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA302. Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.32. Epub 2015 May 1 11. Paul Mainwaring. Use of Biomarkers in CRPC and Future Treatment in Asia. Prostate Int. 3 (2015) S26-S27. Available Online 22 October 2015. http://dx.doi.org/10.1016/j.prnil.2015.10.001. P2287-8882 e2287-903X 12. Paul Mainwaring, Hideyuki Akaza. Emerging Perspectives in Prostate Cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference. Prostate Int. 3 (2015) S1-S4. Available online 22 October 2015. http://dx.doi.org/10.1016/j.prnil.2015.10.1014. P2287-8882 e2287-903X/Copyright © 2015 Asian Pacific Prostate Society. Published by Elsevier. All rights reserved. 13. Paul Mainwaring, Centre for Personalized Nanomedicine, University of Queensland, Australia. The Molecular Pathology of Castrate Resistance Prostate Cancer (CRPC). Prostate Int. 3 (2015) S5-S6. Available Online 22 October 2015. http://dx.doi.org/10.1016/j.prnil.2015.10.013. P22878882 e2287-903X

11

Paul Mainwaring

14. Peter Schmid, Sarah E. Pinder, Duncan Wheatley, Jane Macaskill, Charles Zummit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwn Hadad, Alice Shia, Shah-Jalal Sarker, Louise Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Marke Lackner, Mika Derynck, Timothy Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alistair Thompson. Phase II Randomized Preoperative Window of Opportunity Study of the P13K Inhibitor Pictilisib plus Anastrozole Compare with Anastrozole Alone in Patients with Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2015. 15. Simon J. Harrison, Paul Mainwaring, Timothy Price, Michael J. Millward, Peeter Padrik, Craig R. Underhill, Paul K. Cannell, Francis J. Burrows, Steven D. Reich, Mohit Trikha, Andrew Spencer. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. 2015. 16. E. Gabriela Chiorean, Daniel D. Von Hoff, Michele Bent, Francis P. Arena, Jeffrey R. Infante, Venu G. Bathini, Tina Evans Wood, Paul N. Mainwaring, Robert T. Muldoon, Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Desmond McGovern, Brian Lu, Amy Ko. CA19-9 Decrease at 8 Weeks as Predictor of Overall Survival in a Randomized Phase III Trial (MPACT) of Weekly nab- Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer. Annals of Oncology. 2015. 17. Martin E. Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Se-Hoon Lee, John Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul Mainwaring, Robert E. Hawkins, Lucio Crino, Tae Min Kim, Giacomo Carteni, Wilfried Ernst Erich Eberhardt, Ke Zhang, Kolette Fly, Ewa Matcazk, Maria J. Lechuga, Subramanian Hariharan, Ronald Bukowski. Final Results from the Large Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma. British Journal of Cancer. (2015) 113, 12-19 doi: 10.1038/bjc.2015.196 18. Fred Saad, Neal Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet,Thomas A. Griffin, Peter De Porre, Anil Londhe, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Impact of Bone-Targeted Therapies in Chemotherapy- Naїve Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. European Urology. 2015. 19. P. Swindle and other authors. A Phase I Clinical Trial of CD1c (BDCA-1) + Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer. Journal of Immunotherapy 20. Cora N. Sternberg, Daniel Castellano, Gedske Daugaard, Lajos Géczi, Sebastian J Hotte, Paul N Mainwaring, Fred Saad, Ciro Souza, Miah H Tay, José M Tello Garrido, Luca Galli, Anil Londhe, Peter De Porre, Betty Goon, Emma Lee, Tracy McGowan, Vahid Naini, Mary B Todd, Arturo Molina, Daniel J George. Final Analysis of A Large, Global Early Access Protocol With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. The Lancet Oncology. D-14- 01019R2 21. Shaheenah S. Dawood, Xiudong Lei, Rebecca Dent, Paul N. Mainwaring, Bhawn a Sirohi, Rajendra A. Badwe, Sudeep Gupta, Javier Cortes, Ana M. Gonzalez-Angulo. Effect of Age and Tumour Size on Prognostic Outcome of Women with Breast Cancer. J. Clin. Oncol. 32:5s, 2014 (suppl; abstr 592) 22. Woo Henry, Begbie Stephen, Gogna Kumar, Mainwaring Paul, Murphy Declan, Parnis Francis, Steer Christopher, Davis Ian. Multidisciplinary Concensus: A Practical Guide for the Integration of Abiraterone Into Clinical Practice. Asia Pacific Journal of Clinical Oncology (APJCO). September 2014. Doi: 10.1111/ajco.12264

12

Paul Mainwaring

23. Beer T.M., Armstrong A. J., Rathkopf D. E., Loriot Y., Sternberg C. N., Higano C. S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., Davis I. D., de Bono J. S., Evans C.P., Fizazi K., Joshua A. M., Kim C. S., Kimura G., Mainwaring P., Mansbach H., Miller K., Noonberg S. B., Perabo F., Phung D., Saad F., Scher H. I., Taplin M. E., Venner P. M., Tombal B., PREVAIL Investigators. Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy. N Engl J Med. 2014 Jul 31:371(5):424-33. Doi: 10.1056/NEJMoa1405095. Epub 2014 Jun1. PMIDL24881730 24. Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celectia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung-Soo Kim, Go Kimura, Paul Mainwaring, Harry Mansbach, Kurt Miller, Sarah B. Noonber, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary-Ellen Taplin, Peter M. Venner, Bertrand Tombal for the PREVAIL Investigators. Benefit of Enzalutamide in Chemotherapy-Naїve Metastatic Prostate Cancer. New England Journal of Medicine. June 2014 25. Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul Mainwaring, Michael Green, Prudence Francis, Richard de Boer, Maree Colosimo, Sue Chua, Jacquie Chirgwin, Jane Beith, Richard Bell. System Treatment of HER2-Positive Metastatic Breast Cancer: A Systemic Review. Asia Pacific Journal of Clinical Oncology 2014; (Suppl. 4): 1-14. Doi:10.1111/ajco.12206. http://onlinelibrary.wiley.com/doi/10.1111/ajco.2014.10.issue-s4/issuetoc 26. Paul Mainwaring. Striking the Right Balance for Patients and Innovators: Implications of Association of the Molecular Pathology versus Myriad Genetics Decision. Current Breast Cancer Reports. March 2014, Volume 6, Issue 1, pp 1-2 27. Lee SH, Bang YH, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman, Lowenthal S, Chung HC. Sunitinib in Metastatic Renal Cell Carcinoma: An Ethnic Asian Subpopulation Analysis for Safety and Efficacy. Asian Pacific Journal of Clinical Oncology 2014 Sept; 10(3):237-45. Doi: 10.1111/ahco. 12163. Epub 2014 Feb 27. PMID: 24576311 28. Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang, Cora N. Sternberg, Cezary Szczylik, Jakub Zolnierek, Christian Kollmannsberger, Sun Young Rha, Georg A. Bjarnason, Bohuslav Meichar, Ugo De Giorgi, Viktor Grünwald, Ian D. Davis, Jae-Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael M. Shi, Bernard Escudier for GOLD Trial investigators. Dovitinib versus Sorafenib for Third-Line Targeted Treatment of Patients with Metastatic Renal Cell Carcinoma: An Open-Label, Randomised Phase 3 Trial. Lancet Oncology 2014. Published Online February 17, 2014. http://dx.doi.org/10.1016/S14702045(14)70030-0 29. Dana Rathkopf, Matthew R. Smith, Johann S. de Boer, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles,Tom Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia Higano, Mary-Ellen Taplin, Tom Griffin, Mary Todd, Margaret Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad. Updated Interim Efficacy Analysis, and Long-Term Safety of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA302). European Association of Urology. http://dx.doi.org/10.1016/j.eururo.2014.02.056 30. Dana Rathkopf, Matthew R. Smith, Johann S. de Boer, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel, Joan Carles,Tom Flaig, Eleni Efstathiou, Evan Y. Yu, Celestia Higano, Mary-Ellen Taplin, Tom Griffin, Mary Todd, Margaret Yu, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan, Fred Saad. Updated Interim Analysis, and Long-Term Safety of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Journal of Urology.

13

Paul Mainwaring

31. Fotopoulou C, Vergote I, Mainwaring P, Bidzinksi M, Vermorken JB, Ghamande SA, Harnett P, Del Prete SA, Green JA, Spaczynski M, Blagden S, Gore M, Ledermann J, Kaye S, Gabra H. Weekly AUC2 Carboplatin in Acquired Platinum Resistant Ovarian Cancer With or Without Oral Phenoxodiol, A Sensitizer of Platinum Cytotoxicity: The Phase III OVERTURE Multicentre Randomized Study. Ann Oncol. 2014 Jan;25(1): 160-5. doi: 10.1093/annonc/mdt515. Epub 2013 Dec. 5 32. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyeres ML, Molina A, Cleeland C. Abiraterone Acetate plus Prednisone versus Prednisone Alone In Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer: Patient-Reported Outcome Results of a Randomised Phase 3 Trial. Lancet Oncol. 2013 Nov;14(12):11939-9. doi: 10.1016/S14702045(13)70424-8. Epub 2013 Sep 25. PMID: 24075621 [PubMed – indexed for MEDLINE] 33. John C. Arauja, Gérlyn C. TRudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio V. Serrano, Vsevolod B. Matveev, Eleni Efstathiou, Stephane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goevell, Axel Heidenreich, Johann S. de Bono, Stephen Begbie, Jun H. Hong, Edvardo Richardet, Enrique Gollardo, Prashni Paliwal, Susan Durham, Shinta Cheng, Christopher J. Logothetis. Docetaxel and Dasatinib or Placebo in Men with Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised Double-Blind Phase 3 Trial. The Lancet Oncology. Published Online November 8, 2013. http://dx.doi.org/10.1016/S1470-2045(13)70479-0 34. Se-Hoon Lee, Yung-Jue Bank, Paul Mainwaring, Christina Ng, John W-C Chang, Philip Kwong, Rubi K. Li, Virote Sriuranpong, Chee-Keong Toh, Jinua Yuan, Susan Pitman Lowenthal, Hyun C. Chung. Sunitinib in Metastatic Renal Cell Carcinoma: An Ethical Asian Subpopulation Analysis for Safety and Efficacy. Asia Pacific Journal of Clinical Oncology – 2013-0230 35. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Olandi F, Gravis G, Matveev, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; on behalf of the VENICE investigators. Aflibercept versus Placebo in Combination with Docetaxel and Prednisone for Treatment of Men with Metastatic Castration-Resistant Prostate Cancer (VENICE): A Phase 3, Double-Blind Randomised Trial. Lancet Oncol. 2013 Jun 3. Pii: S1470-2045(13)70184-0. Doi: 1016/S14702045(13)70184-0 36. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ: RECORD1 Trial Study Group. Survival Prediction in /Everolimus-Treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. Eur Urol. 2013 Dec;64(6):994-1002. doi: 1016/j.eururo.2012.11.032. Epub 2012 Nov 21. PMID:23219086 [PubMed – in process] 37. Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, Rothman M, Gagnon DD, Kheoh T, Haqq CM, Cleeland C, de Bono JS, Scher HI. Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic Castration-Resistant Prostate Cancer After Docetaxel Chemotherapy. Ann Oncol. 2013 Apr;24(4): 1017-25. doi: 10.1093/annonc/mdd585. Epub 2012 Nov 14. PMID: 23152362 [PubMed – indexed for MEDLINE] 38. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ,de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquisst E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584. PMID: 23228172 [PubMed – indexed for MEDLINE]

14

Paul Mainwaring

39. Ethan Basch, Karen Autio, Charles J. Ryan, Peter Mulders, Neal Shore, Thian Kheoh, Karim Fizazi, Christophners J. Logothetis, Dana Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles Cleeland. Effect of Abiraterone Acetate on Patient-Reported Pain and Functional Status in ChemotherapyNaїve Patients With Progressive, Metastatic Castration-Resistant Prostate Cancer. The Lancet Oncology. 40. Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng, Joan Carles, Peter F. A Mulders, Ethan Basch, Eric J Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D Mukherjee, Henrik Suttmann, Winald R Gerritsem Thomas W Flaig, Daniel J George, Evan Y Yu, Eleni Efstathiou, Allan Pantuck, Eric Winquist, Celestia S Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas Griffin, Howard I Scher, Dana E Rathkopf, for the COU-AA-302 Investigators. Abiraterone In Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, Dec. 10, 2012. DOI:10 1056/NEJMoa1209096 41. Christopher J Logothetis, Ehtan Basch, Arturo Molina, Karim Fizazi, Scott A North, Kim N Chi, Robert J Jones, Oscar B Goodman, Paul N Mainwaring, Cora N Stermberg, Eleni Efstathiou, Dennis D Gagnon, Margaret Rothman, Yanni Hao, Cameron S Liu, Thian S Kheoh, Christopher M Haqq, Howard I Scher, Johann S de Bono. Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data From the COU-AA-301 Randomised Trial. The Lancet Oncol.2012;13:1210-17. Pub. Online November 9, 2012. http://dx.doi.org/10.1016/S1470-2045(12)70473-4 42. C.N. Sternberg, A.Molina, S. North, P. Mainwairng, K. Fizazi, Y. Hao, M. Rothman, D.D. Gagnon, T. Kheoh, C.M. Haqq, C. Cleeland, J.S. de Bono, H.I. Scher. Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic Castration-Resistant Prostate Cancer After Docetaxel Chemotherapy. Annals of Oncology 00: 1-9, 2012. doi:10. 1093/annonc/mds585 43. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Cediranib with mFOLFOX6 versus Bevacizumab with mFOLFOX6 as First-Line Treatment for Patients with Advanced Colorectal Cancer: A Double-Blind, Randomised Phase III Study (HORIZON III). J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10. PMID: 22965961 [PubMed – indexed for MEDLINE] 44. Karim Fizazi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Kim N. Chi, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stphen Harland, Oscar B. Goodman, Cora N. Sternberg, Jin Hui Li, Thian Kheoh, Christopher M. Haqq, Johann S. de Bono. Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. The Lancet Oncology. Volume 13, Issue 10. Pages 983-992, October 2012. Doi:10.1016/S1470-2045(12)70379-0 (Genitourinary Cancer) Published Online 18 September 2012. 45. Howard I. Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N. Chi, Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul Mainwaring, Mark Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono for the AFFIRM Investigators. Increased Survival With Enzalutamide in Prostate Cancer After Chemotherapy. N Engl Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15. PMID: 22894553 [PubMed – indexed for MEDLINE]

15

Paul Mainwaring

46. Hendrik Van Poppel, Dana Rathkopf, Matthew R Smith, Johann S de Bono, Chrisopher Logothetis, Neal D Shore, Paul de Souza, Karim Fizazi, Peter FA Mulders, Paul Mainwaring, John D Hainsworth, Tomasz M Beer, Scott North, Yves Fradet, Tom Griffin, Youn C Park, Thian Kheoh, Eric J Small, Howard I Scher, Arturo Molina, Charles J Ryan, on behalf of the COU-AA302 investigators. Updated Interim Analysis (IA): Results of Randomized Phase 3 Study COUAA-302 of Abiraterone Acetate (AA) in Metastatic Castration-Resistant Prostate Cancer: The Lancet Oncology 2012; 13:983-92. 47. Richard H. de Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Arlene Chan, Rebeca Melara, Yining Ye, Adeboye H. Adewoye, Robert Sikorski, Peter A. Kaufman. Phase 1b Dose-Finding Study of Motesanib with Docetaxel or Paclitaxel in Patients with Metastatic Breast Cancer. Breast Cancer Res Treat (2012), 135:241-252. doi: 10.1007/s10549012-2135-0. 48. ME Gore, C Porta, L Crino, R Hawkins, G Bjarnason, S Oudad, SH Lee, TH Kim, J Yuan, K Fly, C Szczylik, P Mainwaring. Updated Safety and Efficacy Results for Sunitinib from a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. ? 2012 49. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Drummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patek K, Schadendorf D.; On behalf of the METRIC Study Group. Improved Survival With MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. Epub 2012 Jun 4. PMID:22663011 50. Milward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M, Spear MA. Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel. Invest New Drugs. 2012 June;30(3):1065-73. Epub 2011 Feb 16. PMID:21327495 51. Christopher J. Logothetis, Ethen M. Basch, Arturo Molina, Karim Fizazi, Scott A. North, Kim N. Chi, Robert J. Jones, Oscar B. Goodman, Paul N. Mainwaring, Cora N. Sternberg, Eleni Efstathiou, Dennis D. Gagnon, Margaret Rothman, Yanni Hao, Cameron S. Liu, Thian S. Kheoh, Christopher M. Haqq, Howard I. Scher, Johann S. de Bono. Effect of Abiraterone Acetate on Pain Control and Skeletal-Related Events in Patients With Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: Results of the COU-AA-301 Study. Submitted to Journal of Clinical Oncology March 15 2012. 52. Kim N. Chi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jnr. Exploratory analysis of Survival Benefit and Prior Docetaxel (D) Treatment in COU-hui Li, Thian Kheoh, Christopher M. Haqq, Karim Fizazi. Exploratory Analysis of Survival Benefits and Prior Docetaxel Treatment in COU-AA-301, A Phase 3 Study of Abiraterone Acetate Plus LowDose Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Citation: J Clin Oncol 30, 2012 (supl 5; abstr 15). ASCO GU. San Francisco CA. Feb. 2-4 2012. 53. Ethan Basch, Johann S. de Bono, Howard I. Scher, Arturo Molina, Cora N. Sternberg, Karim Fizazi, Scott A.Norht, Kim N.Chi, Robert J.Jones, Oscar B. Goodman, Paul N. Mainwaring, Amanda Farr, Margaret Rothman, Yanni Hao, Cameron S. Liu, Thian Kheoh, Chris M. Haqq, Eleni Efstathiou, Christopher Logothetis. Pain Control and Delay in Time to Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate: Long-Term Follow-Up. Citation:J Clin Oncol 30, 2012 (suppl 5; abstr 183) ASCO GU Poster. San Francisco CA. Feb. 2-4 2012 54. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; On behalf of REACT Study Group. An International Expanded-Access Programme of Everolimus: Addressing Safety and Efficacy in Patients with Metastatic Renal Cell Carcinoma Who Progress After Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. Eur J Cancer. 2012 Feb.; 48 (3): 324-32. Epub 2011 Jul 29. PMID:21803569

16

Paul Mainwaring

55. Richard H. De Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Arlene Chan, Rebecca Melara, Yining Ye, Adeboye H Adewoye, Robert Sikorski, Peter A. Kaufan. Phase 1b Dose-Finding Study of Motesanib with Docetaxel or Paclitaxel in Patients with Metastatic Breast Cancer. Submitted to CCR January 2012. Final manuscript submission – BCRT February 2012 56. S.-H. Lee, Y.-J. Bang, P. Mainwairng, C. Ng, J. W.-C. Chang, P. Kwong, R. K. Li, V. Sruranpong,, C.-K. nToh, J. Yuan, S. P. Lowenthal, H.C. Chung. Sunitinib in Metastatic Renal Cell Carcinoma: An Ethnic Asian Subpopulation Analysis for Safety and Efficacy. Annals of Oncology. 57. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Hörsch D., Winkler R.E., Klimovsky J., Lebwohl D., Jehl V., Wolin E.M., Oberg K., Van Dutsem E., Yao J.C.; RADIANT-2 Study Group. Everolimus plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendorcrine Tumours Associated with Carcinoid Syndrome (RADIANT-2): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet. 2011 Dec 10;378(9808): 2005-12. Epub 2011 Nov. 25.PMID:22119496 58. De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B. Jr, Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., Hutson T.E., Chang T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., Ellard S.L., Fléchon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I.: On behalf of COU-AA-301 Investigators. Abiraterone and Increased Survival in Prostate Cancer. N Eng J Med. 2011 May 26;364(21):1995-2005. PMID: 21612468 59. Johann S. de Bono (M.D., Ch.B, PhD.), Christopher J., Logothetis (M.D.), Arturo Molina (M.D.), Karim Fizazi (M.D., PhD.), Scott North (M.D.), Kim N, Chi. (M.D.), Robert J. Jones (M.D.), Oscar B. Goodman, Jr. (M.D., PhD.), Fred Saad (M.D.), John N. Staffurth (M.D., Paul Mainwaring (M.D., M.B., B.S.), Stephen Harland (M.D.), Thomas W. Flaig, M.D.), Thomas E. Hutson, (D.O., Pharm D.), Tina Cheng (M.D.), Helen Patterson (M.D.), John D. Hainsworth (M.D.), Charles J . Ryan (M.D.), Cora N. Stemberg (M.D.), Susan L. Ellard (M.D.), Aude Fléchon (M.D., PhD.), Mansoor Saleh (M.D.), Mark Scholz (M.D.), Eleni Efstathiou (M.D., PhD.), Andrea Zivi (M.D.), Diletta Bianchini (M.D.), Yohann Loriot (M.D.), Nicole Chieffo (M.B.A.), Thian Kheoh (PhD.), Christopher M. Haqq (M.D., PhD.), Howard I. Scher (M.D.) for the COU-AA-301 Investigators. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N.Engl J Med 2011;364:1995-2005/May 26 2011 60. Smith I.E., Pierga J.Y., Biganzoli L., Cortés-Funes H., Thomssen C., Pivot X., Fabi A., Xu B., Stroyakovskiy D., Franke F.A., Kaufman B., Mainwaring P., Pienkowski T., De Valk B., Kwong A., González-Trujillo J.L., Koza I., Petrakova K., Pereira D., Pritchard K.I..; On behalf of the ATHENA Study Group. First-Line Bevacizumab plus Taxane-Based Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: Safety and Efficacy in an Open-Label Study in 2,251 Patients. Ann Oncol. 2011 Mar;22(3):595-602. Epub 2010 Sep 5. PMID:20819780 61. Javier Cortes, Joyce O’Shaughnessy, David Loesc, Joanne L Blum, Linda T Vahdat, Katarina Petrakova, Philippe Chollet, Alexey Manikas, Veronique Diéras, Thierry Delozier, Vladimir Vladimirov, Fatima Cardoso, Han Koh, Phillipe Bougnous, Corina E.Dutcus, Seth Seegobin, Denis Mir, Nicole Meneses, Jantien Wanders, Chris Twelves: On behalf of the EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice versus E7389) Investigators. Eribulin Monotherapy versus Treatment of Physician’s Choice in Patients With Metastatic Breast Cancer (EMBRACE):A Phase 3 Open-Label Randomised Study. Lancet 2011;377:914-23. Published on-line March 3 2011 62. Millward M., Mainwaring P., Mita A., Federico K., Lloyd G.K., Reddinger N., Nawrocki S., Mita M., Spear M.A.. Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel. Invest New Drugs. 2011 Feb 16. PMID:21327495

17

Paul Mainwaring

63. Motzer R. J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grünwald V., Thompson J.A., Figlin R.A., Hollaender N., Kay A., Ravaud A.; On behalf of RECORD-1 Study Group. Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors. Cancer. 2010 Sept. 15;116(18):4256-65 64. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., Kang Y.K.. Mainwaring P. On behalf of ToGA Trial Investigators. Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase III, Open-Label, Randomized Controlled Trial. Lancet. 2010 Aug. 28;376 (9742): 687-97. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.PubMed PMID: 20728210. 65. Hill J, Treasure T.; On behalf of the Guideline Development Group. Reducing the Risk of venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital: Summary of the NICE Guideline. Heart. 2010 June;96(11):879-82. No abstract available. PMID:20478866 66. Roberto Pili, Mark Rosenthal, Mainwaring Paul, Guy Van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph Leach, Shirley Wong, Peter Clingan. Phase II Study of the Addition of ASA404 (Vadimezan), 5, 6- dimethylxanthenone-4-acetic acid (DMXAA) to Docetaxel in Castration-Refractory Metastatic Prostate Cancer. Clinical Cancer Research 2010 May 15; 16 (10): 2906-14. Epub 2010 May 11. PubMed PMID: 20460477 67. Hill J, Treasure T. On behalf of the National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the Risk of Venous Thromboembolism in Patients Admitted to Hospital: Summary of NICE Guidance. BMJ. 2010 Jan 27;340:c95. doi: 10.1136/bmh.c95. No abstract available. PMID:20106897 68. McKeage M. J. Reck M, Jameson M.B., Gibbs D, Rosenthal M, Mainwaring P, Von Pawel J, Freitag L, Sullivan R. Phase II Study of ASA404 (Vadimezan, 5, 6-Dimethylxanthenone-4-Acetic Acid/DMXAA 1800mg/m2 Combined with Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2009 Aug;65 (2): 192-7. Epub 2009 May 5. Pubmed PMID:19409645 69. Alberto Sobrero, Scott Young, Margaret Balcewicz, Silvana Chiarra, Ramon Perez Carrion, Paul Mainwaring, John Gapski, Stephen Clarke, Bernd Langer, Stephen Ackland. AVIRI Trial Investigators. Phase IV study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. Oncology 2009; 77 (3-4):256.Following 119. Chiara, Silvia [corrected to Chiara, Silvana]. PubMed PMID: 19628950 70. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrodljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and Efficacy Sunitinib for Metastatic Renal Cell Carcinoma (mRCC): An Expanded Access Trial. Lancet Oncol. 2009 Aug; 10 (8): 757-63. Epub 2009 Jul 15. PubMed PMID: 19615940 71. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Dibartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D.; On behalf of the First BEAT investigators. Safety and Efficacy of First-Line Bevacizumab with Folfox, Xelox, Folfiri and Fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 2009. April 30 72. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RT, TabahFisch I, Cassidy J. Two Different First-Line 5-Fluororacil Regimens With or Without Oxaliplatin in Patients with Metastatic Colorectal Cancer. Ann Oncol. 2009 Feb;20(2):244-50. Epub 2008 Oct 14. PMID:18854549

18

Paul Mainwaring

73. Tarhini AA, Milward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM. A Phase 2, Randomized Study of SB-485233, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma. Cancer. 2009 Feb 15;115(4):859-68. PMID:19140204 74. McKeage MJ, Von Pawl J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PM, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised Phase II Study of ASA404 Combined With Carboplatin and Paclitaxel in Previously Untreated Advanced NonSmall Cell Lung Cancer. Br J Cancer. 2008 Dec 16;99(12):2006-12 PMID:19078952 75. A. Sobrero, S. Ackland, S. Clarke, R. Perez-Carrión, S. Chiara, J. Gapski, P. Mainwaring, B Langer, S. Young (for the AVIRI Trial Investigators. Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFORI) in First-Line Metastatic Colorectal Cancer. August. 2008 76. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. On behalf of the RECORD-1 Study Group. Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial. Lancet. 2008 Aug 9;372(9637):449-56. Epub 2008 Jul 22. PMID:18653228 77. Ahmad A. Tarhini, Michael Millward, Paul Mainwaring, Richard Kefford, Ted Logan, Anna Pavlick, Steven J.Kathman, Kevin H. Laubscher, Mohammed M. Dar, John M. Kirkwood. A Phase II, Randomized Study of SB-485232, rhIL-18, in Patients with Previously Untreated Metastatic Melanoma. SB-485232006. Cancer. 04-130 IL-18. January 2008 78. Mark J. McKeage, Joachim Von Pawel, Michael B. Jameson, Mark Rosenthal, Richard Sullivan, David Gibbs, Paul Mainwaring, Martin Reck, Monique Serke, Jean-Jacques Lafitte, Christos Chouaid, Lutz Freitag, and Elisabeth Quoix.. Randomized Phase Ib/II Study of 5,6Dimethylxanthenone-4-Acetic Acid (DMXAA/ASA404) Combined with Carboplatin and Paclitaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer. Submitted J Clin Oncol 79. Vera Hirsh, John Glaspy, Paul Mainwaring, Christian Manegold, Rodryg Ramlau and Joseph E Eid. Phase II Study of Two Dose Schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Anemic Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy. Trials 2007 Mar 6;8:8. PMID:17341293 80. Mainwaring PN. Angiogenesis Inhibitors in Cancer - Clinical Applications. Australian Prescriber. 29 (1) 2006. 81. Nicholson C, Jackson CL, Wright B, Mainwaring P, Holliday D, Lankowski A and Kardash C. Online Referral and OPD Booking From The GP Desktop - Building Electronic Linkage Between Hospital and Community Providers. Australian Health Review August 2006 Aug;30(3):397-404. PMID:16879099 82. Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DN. The Immune Response to Breast Cancer, and the Case for DC Immunotherapy. Cytotherapy. 2004;6(2):154-63. Review. PMID:15203992 83. Mainwaring P, van Cutsem E, Makris, A. A Randomised Study of Oral UFT (Uracil/Tegafur) Plus Leucovorin or Parenteral 5-Fluorouracil plus Leucovorin in Patients With Metastatic Colorectal Cancer. Eur J Cancer 2004 84. Van Cutsem E, Mainwaring P, van Laethem J, Husseini F, Twelves C, Propper D, Bridgewater J, Stuart N, Punt C, Carmichael J, Ravic M, Yule SM. A Randomised Phase II Multi-Centre Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent in 5-Fluorouracil Pre-Treated Colorectal Cancer. Ann Oncol submitted

19

Paul Mainwaring

85. Mainwaring P.N. Judson I. High Dose Rapid Schedule Treatment with Ifosfamide, Etoposide, Cyclophosphamide and G-CSF For Poor Prognosis Sarcomas. (Accepted subject to revision Sarcoma) 86. Mainwaring PN, Cunningham D, Gregory W, Hoskin P, Hancock B, Norton AJ, MacLennan K, Smith P, Hudson GV, Linch D. Mitoxantrone is Superior to Doxorubicin in a Multi-agent Weekly Regimen for Patients Older Than 60 With High-Grade Lymphoma: Results of a BNLI Randomized Trial of PAdriaCEBO versus PMitCEBO. Blood. 2001 May 15;97(10):2991-7. 87. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Singhal S, Mehta J. The Role of Autologous Transplantation in Patients with Multiple Myeloma aged 65 Years and Over. Bone Marrow Transplant; 25(5):533-9 2000 88. Sumpter K, Powles RL, Raje N, Ramiah V, Kulkarni S, Treleaven J, Mainwaring PN. Oral Idarubicin As A Single-Agent Therapy in Patients With Relapsed or Resistant Multiple Myeloma. Leuk Lymphoma. 1999 Nov;35(5-6):593-7. PMID:10609797 89. Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE. Clinical Studies of Apoptosis and Proliferation in Breast Cancer. Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review. 90. Dowsett M, Detre S, Ormerod MG, Ellis PA, Mainwaring PN, Titley JC, Smith IE. Analysis and Sorting of Apoptotic Cells from Fine-Needle Aspirates of Excised Human Primary Breast Cancer. Cytometry. 1998 Aug 1;32(4):291-300. PMID 9701398 91. Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M. Comparison of In Situ Methods to Assess DNA Cleavage in Apoptotic Cells in Patients with Breast Cancer. J Clin Pathol. 1998 Jan;51(1):34-7. PMID:9577369 92. Mainwaring PN, Nicolson MC, Hickish T, Penson R, Joel S, Slevin M, Smith IE. Continuous Infusional Topotecan in Advanced Breast and Non-Small Cell Lung Cancer: No Evidence of Increased Efficacy. Br J Cancer. 1997;76(12):1636-9. PMID:9413954 93. Mainwaring PN, Atkinson H, Chang J, Moore J, Hancock BW, Guillou PJ, Oskam R, Gore ME. Differential Responses to Chemoimmunotherapy in Patients with Metastatic Malignant Melanoma. Eur J Cancer 1997 Aug;33(9):1388-92. PMID:9337679 94. Gregory RK, Mainwaring PN, Hill M, Pyle L, Ramsden MA, Gore ME. Can Paclitaxel be Delivered by Continuous Ambulatory Infusion? Br J Cancer 1997 76: Suppl 1: P09. 95. Gore, M. E., Mainwaring, P. N., Macfarlane, V., A'Hern, R., Osborne, R., Harper, P., Quigley, M., Slevin, M., Jones, A., Mansi, J. Blake, P. A Randomized Study of High versus Standard Dose Carboplatin in Patients with Advanced Epithelial Ovarian Cancer. J Clin Oncol; 16(7): 2426-34. 96. Mainwaring, P.N., Atkinson, H., Chang, J., Moore, J., Hancock, B.W., Guillou, P.J., Oskam, R., Gore, M.E. Differential Responses to Chemoimmunotherapy in Patients with Metastatic Melanoma. Eur J Cancer 1997, Vol.33, No.9, pp.1388-1392 97. Mainwaring PN, Gore ME. The Importance of Dose and Schedule in Cancer Chemotherapy: Epithelial Ovarian Cancer. Anticancer Drugs. 1995 Oct;6 Suppl 5:29-41. PMID:8845493 98. Mainwaring, P.N., Grygiel, J.J. Interaction of 5-Fluorouracil with Folates. Aust New Zealand J Med 25; 1: 60 1995 99. Childs AM, Coates AS, Cox KM, Mainwaring PN. Severe Vascular Adverse Effects with Thrombocytopenia and Renal Failure Following Emetogenic Chemotherapy and Ondansetron. Ann Oncol 1994 Jan;5(1):98. PMID:8172803

20

Paul Mainwaring

Book Chapters 1.

Mainwaring P.N., Tattersall M.H.N. An Integrated Approach to the Management of Cervix Cancer. Ed. Professor DM Luesley Birmingham Health Authority.

2.

Smith I.E., Mainwaring, P.N. Primary Medical Therapy for Breast Cancer, Textbook Chapter in The Management of Breast Cancer, G Bonadonna Ed. Martin Dunitz, London 1997

3.

Mainwaring P.N., Dowsett, M. LHRH Superagonists And Antagonists In The Treatment Of Breast Cancer. Endocrinology Of The Breast - A Manni, Ed. Humana Press Inc, Totowa, New Jersey, U.S.A. 1997

4.

Mainwaring, P.N. & Timothy, A.R. PET: Diagnosis and Management of Lymphomas in Annual of Lypmhoid Malignancies, Ed Cavalli, F. Matin Dunitz Publishers, London, 2000

5.

Mainwaring, P.N.. Current and Future Strategies for the Management of Colorectal Cancer. Primary Care in the New NHS, The Journal of Primary Care Groups and Trusts, Autumn 2000.

6.

Mainwaring, P.N.. Medical Developments the Management of Colorectal Cancer. Primary Care in the New NHS, The Journal of Primary Care Groups and Trusts, Autumn 2001.

7.

C. Osterling, Mainwaring PN Treatment Strategies Targeting Inhibition of Epidermal Growth Factor Receptor Expression in Advanced cancer. Current Medical Literature, October 2002

8. Mainwaring PN. Scientific Evidence and Expert Opinion for Adjuvant Chemotherapy in Colorectal Cancer. Key Advances Series, London 2003 9.

Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. Phase II Study of Two Dose Schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Anemic Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Receiving Chemotherapy.

MD Thesis Proliferation, Apoptosis And Control Of Apoptosis In The Endocrine Management Of Human Breast Cancer The University of London

21

Paul Mainwaring

Published Abstracts 1.

Toni K. Choueiri, Thomas Powles, Bernard Escudier, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce Roth, Katrina Peltola, Jae Lyun Lee, Daniel Y. C. Heng, Manuela Schmidinger, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Sumanta Pal, Thomas E. Hutson, Robert J. Motzer. Overall Survival (OS) in METEOR, A Randomised Phase 3 Trial of Cabozantinib (Cabo) versus Everolimus (Eve) in Patients (pts) with Advanced Renal Cell Carcinoma (RCC). ASCO (American Society of Clinical Oncology). Chicago June 3 – 7, 2016

2.

O. Sartor, S. Oudard, L. Sengeløv, G. Daugaard, F. Saad, S. Hansen, M. Hjelm-Eriksson, J. Jassem, A. Thiery Vuillemin, O. Caffo, D. Castellano, P.N. Mainwaring, J. Bernard, L. Shen, M. Chadjaa, K. Fizazi. Carbazitaxel vs Docetaxel in Chemotherapy-Naïve (CN) Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): a 3-Arm Phase III Study (FIRSTANA). ASCO (American Society of Clinical Oncology). Chicago June 3 – 7, 2016.

3.

Paul N. Mainwaring, Christopher Pyke, Darren Korbie, Michael Pheasant, Dennis Gascoigne, Ken Musgrave, Kate O’Neill, Kelly McGrath, Mathias Trau. Multi-Platform Quality Assurance (QA) Comparison of Next-Generation Sequencing 9NGS) Technologies Incorporating Novel Simultaneous Mutation and Copy Number Variation (CNV) Reporting. ASCO (American Society of Clinical Oncology). Chicago. May 29 – June 2, 2015.

4.

Beer T.M., Armstrong A., Sternberg C.N., Higano C.S., Rathkopf D.E., Loriot Y., Saad F., Joshua A.M., De Bono J.S., Venner P., Carles J., Mainwaring P., Evans C.P., Parki T., Mansbach H., Bhattacharya S., Van Os S., Phung D., Tombal B. Enzalutamide (ENZA) in Men with Chemotherapy-Naïve Metastatic Castration-Resistanct Prostate Cancer (mCRPC): Final Analysis of the Phase 3 PREVAIL Study. ASCO (American Society of Clinical Oncology). Chicago. May 29 – June 2, 2015.

5.

Paul Mainwaring, Glenn Liu, Ji Youl Lee, Andrey Semenov, Sheela Tejwani, Primo Lara, Jr, Géralyn C. Trudel, Antonieta Sosa, Thian Kheoh, Margaret K. Yu, Brenden Rooney, Byron Espina, Matthew R. Smith, Eric J. Small. SPARTAN – A Randomized Double-Blind, Comparative Study of ARN-509 plus Androgen Deprivation Therapy (ADT) vs ADT Along in Non-Metastatic Catrastion-Resistant Prostate Cancer (MO-CRPC). USANZ (Urology Society of Australia and New Zealand) 68th Annual Scientific Meeting. Adelaide. 11-14 April 2015

6.

Paul Mainwaring, Noan Minh Chau, Ph-Hui Chiang, Wing Ming Ho, Elizabeth Hovey, Ji Youl Lee, Siobhan Ng, See-Tong Pang, Phillip Parente, Vichien Srimuninnimit, Hui Meng Tan, MiahHiang Tay, Anil Londhe, Janis Mae Pagtakhan-Galgana, Max Van Kooten Losio, Arturo Molina. Early Access Protocol with Abiraterone Acetate for Patients in the Asia-Pacific Region with Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. USANZ (Urology Society of Australia and New Zealand) 68th Annual Scientific Meeting. Adelaide. 11-14 April 2015.

7.

Ian D. Davis, Choung-Soo Kim, Go Kimura, Weber Lu, Sarah B. Noonberg, Frank Perabo, Suman Bhattacharya, De Phung, Bertrand Tombal, Tomasz M. Beer, P.N. Mainwaring. Enzalutamide in Men with Chemotherapy-naїve Metastatic Castration Resistant Prostate Cancer (mCRPC): Primary and Australian/Asian Regional Results of the Phase 3 PREVAIL Study. Abstract. World Cancer Congress. Melbourne. December 3-6, 2014.

8.

Darren Korbie, Michael Pheasant, Paul Mainwaring, Christopher Pyke, Kate O’Neill, Erica Lin, David Wall, Carissa Phillips, Ken Musgrave, Matt Trau. New Paradigms in Clinical Cancer Pathology: Comprehensive Molecular Profiling of Prospective Breast Cancer Samples in 7 Days Using Benchtop Seqencing Platforms. IABCR. (International Association for Breast Cancer Research) 14-17 September 2014. Novotel Sydney Manly Pacific.

22

Paul Mainwaring

9.

C. Sardjono, J. Bower, P. McCloud, P. Mainwaring, S. Sewak, S. Wong, D. Kotasek, S.H. Lee, J.S. Chung, J. Sanmugarajah, S. Troon, D. Yip, S. Singh, D. Crump, D. De Souza. A Phase II Study of Sequential Therapy With Pazopanib Followed By Everolimus in Metastatic Renal Cell Cancer – Study Update. Abstract MOGA (Medical Oncology Group of Australia Incorporated). Sydney 6-8 August 2014.

10. Cora N. Sternberg, Gédske Daugaard, Lajos Geczi, Sebastien J. Hotee, Paul N. Mainwaring, Fred Saad, Ciro Souza, Miah T. Tay, José M. Tello Garrido, Luca Galli, Anil Londhe, Peter De Porre, Dan Atlan, Betty Goon, Emma Lee, Tracey McGowan, Vahid Naini, Mary B. Todd, Arturo Molina, Daniel J. George. Final Analysis of a Large, Open-Label Global Early Access Protocol With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. Abstract #5061 General Poster Session: Genitoruinrary (Prostate) Cancer. ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 2, 2014. 11. Shaheenah S. Dawood, Xiudong Lei, Rebecca Dent, Paul N. Mainwaring, Bhawn a Sirohi, Rajendra A. Badwe, Sudeep Gupta, Javier Cortes, Ana M. Gonzalez-Angulo. Effect of Age and Tumour Size on Prognostic Outcome of Women with Breast Cancer. ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 2, 2014. 12. Paul N. Mainwaring, Christopher Pyke, Darren Korbie, Michael Pheasant, Kate O’Neill, Ken Musgrave, Mattias Trau. Quality Assurance Study of Real-Time Targeted Massive Parallel Sequencing (MPS) Comprehensive Cancer Panel (CCP) and Network Pathway Analysis in Early Breast Cancer (EBC). Abstract ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 3 2014. 13. Andrew Armstrong, Bertrand Tombal, Cora N. Sternberg, Celestia Higano, Dana E. Rathkopf, Yohann Loriot, Fred Saad, Anthony M. Joshua, Johann De Bono, Peter Venner, Joan Charles, Paul Mainwaring, Christopher P. Evans, Sarah B. Noonberg, Hank Mansbach, Suman Bhattacharya, Frank Perabo, De Phung, Tomasz B. Beer. Primary, Secondary and Quality of Life, Endpoint Results from PREVAIL, a Phase 3 Study of Enzalutamide in Men with Metastatic Castrate Resistant Prostate Cancer. Abstract. ASCO (American Society of Clinical Oncology). Chicago. May 30 – June 3 2014. 14. Neal D. Shore, Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Efficacy and Long-Term Safety Analysis of Study COU-AA-302: Abiraterone Acetate (AA) Plus Prednisone (P) in Chemotherapy- Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC). AUA (American Urological Association) Abstract.16th – 21st May 2014. Orlando,Florida, USA. 15. A/Prof Christopher Pyke, A/Prof Paul Mainwaring, Prof. Matt Trau, Dr Glenn Francis, Dr Darren Korbie, Dr Michael Pheasant. Quality Metric Study of Real-Time Targeted Massive Parallel Sequencing (MPS) (Ampliseq Comprehensiv Cancer Panel (CCP) and Bioinformatics in Early Breast Cancer (EBC) Using Life Technologies Ion Proton System. RACS Annual Scientific Congress. ANZCA Annual Scientific Meeting. Sands Expo and Convention Centre, Marina Bay Sands, Singapore. May 5 – 9 2014. 16. Paul Mainwaring, Evan Y. Yu, Fred Saad, Anil Londhe, Neil Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, John D. Hainsworth, Thomasz M. Beer, Scott North, Eric J. Small, Howard I. Scher, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan. Association of Alkaline Phosphatase With Clinical Outcomes in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results From COU-AA-302. Urological Society of Australia and New Zealand (USANZ). 16-19 March 2014. Brisbane. Australia

23

Paul Mainwaring

17. Evan Y. Yu, Fred Saad, Anil Londhe, Neil Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D.Hanisworth, Tomasz M. Beer, Scott North, Erica J. Small, Howard I. Scher, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan. Association of Alkaline Phosphatase (ALP) With Clinical Outcomes in Chemotherapy-Naïve Patients (pts) with Metastatic CastrationResistant Prostate Cancer (mCRPC): Results from COU-AA-302. Abstract #123692. ASCO GU. 30th January – 1st February 2014. San Francisco Marriott Marquis, San Francisco 18. T.M. Beer, A. Armstrong, C. Sternberg, C. Higano, P. Iverson, Y. Loriot, D.E. Rathkopf, S. Bhattacharya, J. Carles, J. de Bono, C.P. Evans, A. Joshua, C. Kim, G. Kimura, P. Mainwaring, H. Mansbach, K. Miller, S. Noonber, P. Venner, B. Tombal. Enzalutamide in Patients with Chemotherapy-Naïve Metastatic Prostate Cancer: Results from the Phase 3 PREVAIL Study. Abstract. ASCO GU. 30th January – 1st February 2014. San Francisco Marriott Marquis, San Francisco 19. D. Korbie, M. Pheasant, K. O’Neill, P. Mainwaring, M. Trau. Technical Assessment of Multiplex Targeted Resequencing Applications for Somatic Mutation Detection: Amplicon Representation, Reproducibility and Bias of the Ampliseq Comprehensive Cancer Panel and TruSight Tumour Panel Across 250 Patient Samples. San Antonio Breast Cancer Symposium. San Antonio, Texas. 10th – 14th December 2013. 20. Paul de Souza, Dana Rathkopf, Matthew R Smith, Peter F.A. Mulders, Paul Mainwaring, Scott North, Thomas Griffin, Youn C. Park, Arturo Molina, Charles J. Ryan. Long-Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Study COU-AA-302 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy. Prostate Cancer World Congress 2013. 6-10th August 2013. Melbourne Convention and Exhibition Centre, Melbourne, Victoria, Australia. 21. Michele Reni, Daniel D. Von Hoff, E. Gabriela Chiorean, Thomas Ervin, Francis P. Arena, Jeffrey R. Infante, Venu Bathini, Tina Wood, Paul Mainwaring, Robert Muldoon, Philip Clingan,Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu. CA19-9 Decrease and Kinetics in a Randomized Phase III Trial (MPACT) of Weekly nabPaclitaxel (nab-P) plus Gemcitabine (G) vs G Alone in Patients With Metastatic Pancreatic Cancer (PC). ESMO 15th World Congress On Gastrointestinal Cancer. 3rd-6th July 2013. Barcelona, Spain. 22. E. Gabriela Chiorean, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, Jeffrey R. Infante, Venue Gopal Bathini, Tina Evans Wood, Paul N. Mainwaring, Robert T. Muldoon, Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu. CA19-9 Decrease at 8 Weeks as a Predictor f Overall Survival (OS) in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel (nab-P) plus Gemcitabine (G) vs G Alone in Patients with Metastatic Pancreatic Cancer. Abstract #117231. ASCO (American Society of Clinical Oncology), 31st May – 4th June 2013. 23. Dana Rathkopf, Matthew R Smith, Johann S de Bono, Christopher Logothetis, Neal D Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Long Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy (COU-AA-302). Abstract #111574. ASCO (American Society of Clinical Oncology), 31st May – 4th June 2013. 24. Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Daniel Ford, Loic Mourey, Phillip Parente, Shapiro, Igor Latorzeff, Istvan Bodrogi, Choung-Soo Kim, Albert Font, Roanne Segal, Hendrik Pieter Van Den Berg, Wenping (Wendy) Zhang, Mustapha Chadjaa, Johann Sebastian De Bono. Proselica Study Update: Comparison of Two Doses of Cabazitaxel (Cbz) + Prednisone (P) in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with a Docetaxel (D)-Containing Regimen. Abstract #112489. Poster #TPS5099^. ASCO (American Society of Clinical Oncology), 31st May – 4th June 2013.

24

Paul Mainwaring

25. Daniel J. George, Tracy McGowan, Gedske Daugaard, Thomas W. Flaig, Lajos Géczi, Sebastien J. Hotte, Paul N. Mainwaring, Fred Saad, Matthew R. Smith, Ciro de Souza, Cora N Sternberg, Miah Hiang Tay, José Manuel Tello Garrido, Anil Londhe, Vahid Naini, Mary Beth Todd, Arturo Molina. Interim Safety Results of a Global Early Access Protocol (EAP) of Abiraterone Acetate (AA) in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressing after Taxane-Based Chemotherapy. Abstract #113212. ASCO (American Society of Clinical Oncology), 31st May – 4th June 2013. 26. Paul de Souza, Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Neal D. Shore, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D Hainsworth, Thomas M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Long Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Study COU-AA-302 for Metastatic CastrationResistant Prostate Cancer (mCRPC) Without Prior Chemotherapy. ASCO (American Society for Clinical Oncology) Annual Meeting. 31st May – 4th June 2013. Chicago IL. USA. 27. Fred Saad, Neal D Shore, Hendrik Van Poppel, Dana Rathkopf, Matthew R Smith, Johann S de Bono, Christopher Logothetis, Paul de Souza, Karim Fizazi, Peter F A Mulders, Paul Mainwaring, John D Hainswaroth, Tomasz M Beer, Scott North, Yves Fradet, Tom Griffin, Thian Kheoh, Eric J Small, Howard I Scher, Arturo Molina, Charles J Ryan. Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy – Interim Analysis of the COU-AA-302 Phase 3 Trial. (AUA – American Urological Association), San Diego, CA; May 4-8, 2013. 28. Neal Shore, Ethan Basch, Charles J. Ryan, Peter Mulders, Thian Kheoh, Karim Fizazi, Christopher J. Logothetis, Dana Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles Cleeland. The Impact Of Abiraterone Acetate Therapy on Patient-Reported Pain and Functional Status in Chemotherapy Naїve Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer – Results From An Updated Analysis. Poster #784. AUA (American Urological Association) Annual Meeting, 4th -8th May 2013. San Diego. CA. USA. 29. Hendrik Van Poppel, Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F. A. Mulders, Paul Mainwaring, John D. Hainsworth. Thomasz M. Beer, Scott North, Yves Fradet, Tom Griffin, Yun C. Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan on behalf of the COU-AA-302 Investigators. Updated Interim Analysis: Results of Randomized Phase 3 Study COU-AA-302 of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Without Prior Chemotherapy. Poster. European Association of Urology Congress. 15th – 19th March 2013. Milan, Italy. 30. Dana Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas Griffin, Youn C Park, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan. Long Term Safety and Efficacy Analysis of Abiraterone Acetate (AA) plus Prednisone (P) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Without Prior Chemotherapy (COU-AA-302). Poster. ASCO Genitourinary Cancers Symposium. 14th – 16th February 2013. Florida. 31. Fred Saad. Lead author on behalf of COU-AA-302 Investigators. Encore Presentations: Abiraterone Study 302 Interim Analysis, OS 43%. QUA (Quebec Urological Association). 9th – 11th November 2012. Quebec. 32. Paul de Souza. Lead author on behalf of COU-AA-302 Investigators. Encore Presentations: Abiraterone Study 302 Interim Analysis, OS 43%. COSA (Clinical Oncological Society of Australia). 13th – 15th November 2012. Brisbane. Australia.

25

Paul Mainwaring

33. P. Mainwaring, O.B.Goodman, Jr, K.N. Chi, A.Molina, C.Logothetis, R.J. Jones, J.N. Staffurth, S. North, N. Vogelzang, F. Saad, S. Harland, J. Li, T. Kheoh, C.M. Haqq, H.I Scher, K. Fizazi. A Phase 3 Study COU-AA-301of Abiraterone Acetate (AA) Plus Prednisone (P) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): an Exploratory Analysis of Prior Docetaxel (D) Treatment and Survival Benefit. COSA 13th -15th November 2012. Brisbane, Australia. 34. Ethan Basch, Charles J. Ryan, Thian Kheoh, Karim Fizazi, Yanni Hao, Thomas Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles Cleeland, Paul Mainwaring. The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naїve Patients With Progressive, Metastatic Castration-Resistant Prostate Cancer (mCRPC). ESMO 2012 (Vienna, September 28 – October 2). 35. Joachim von Pawel, Vera Gorgounova, Martin Reck, Dariusz M. Kowalski, Aurore Allard. Mustapha Chadjaa, Augustin Rey Jaafar Bennouna Francesco Grossi on behalf of the DISRUPT Investigators. DISRUPT: A Randomized Phase 2 Trial of OMBRABULIN (AVE8062) Combined With a Taxane-Platinum Regimen in the First-Line Treatment of Metastatic Non-Small Lung Cancer (NSCLC). Abstract – ESMO Vienna 28 Sept. – 2 Oct. 2012 36. Fred Saad. Lead Author on behalf of the COU-AA-302 Investigators. Encore Presentations: Abiraterone Study 302 Interim Analysis, OS 43%. QUA (Quebec Urological Association) Congress. Saint Paulin, Quebec. 14th 16th September 2012 37. S. Oudard, L. Sengelov, P. Mainwaring, A. Thiery-Vuillemin, C. Theodore, E. Kulikov, J. Yachnin, I. Kocak, V. Kataja, M. Luukkaa, A Nosov, M. Hjelm-Erkisson, J. Bubis, L. Shen, M-L. Risse, O. Sartor. FIRSTANA First-Line Use of Cabazitaxel in Chemotherapy-naїve Patients With Metastatic Castration-Resistant Prostate Cancer: A Three-Arm Study in Comparison With Docetaxel. Poster, ASCO 1-5 June 2012 38. Oscar B. Goodman, Kim N. Chi, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholoas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jinhui Li, Thian Kheoh, Chritopher M. Haqq, Howard I. Scher, Karim Fizazi. Exploratory Analysis of Survival Benefit and Prior Docetaxel Treatment in COU-AA-301, A Phase 3 Study of Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. 39. Paul Mainwaring, Carmelo Bengala, Antoinette R. Tan, REgigiusz Kaleta, M. Brent McHenry, Ioannis Lainas, Pamela L. Clemens, Pierfranco Conte. A Phase 1 Study of Ixabepilone and Lapatinib in Patients With Her2-Positive, Pretreated Metastatic Breast Cancer. 40. C.J. Ryan, M.R. Smith, J.S. de Bono, A. Molina, C. Logothetis, P. De Souza, K. Fizazi, P. Mainwaring, J.R. Piulats, S. Ng, J. Carles, P.F.A. Mulders, T. Kheoh, T. Griffin, E.J. Small, H. Scher, D. Rathkopf, on behalf of the COU-AA-302 investigators. Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase 3 Study of Abiraterone Acetate (AA) in ChemotherapyNaїve Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRC). Abstract ASCO Annual Meeting, Chicago, June 1-5 2012. 41. Mario Eisenberger, Anne-Claire Hardy-Bessard, Loїc Mourey, P. Mainwaring, Daniel Ford, Jeremy Shapiro, Joan Carles Galceran, Siobhan Ng, Thierry Gil, Boris Alekseev, Sergey Ivanov, Thomas Facchini, Eric Legouffe, Olg Apolikhin, Hardev Pandha, Aart Beeker, Oleg Karaykin, Wendy Zhang, Mustapha Chadjaa, Johann S de Bono. Comparison of Two Doses of Cabazitaxel Plus Prednisone in Patients with Metastatic Castration-Resistant (mCRPC) Previously Treated With Docetaxel (D)-Containing Regimen. PROSELICA Trial. Abstract submitted to ASCO Annual Meeting. June 1-5 2012

26

Paul Mainwaring

42. Kim N. Chi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jnr. Exploratory analysis of Survival Benefit and Prior Docetaxel (D) Treatment in COU-hui Li, Thian Kheoh, Christopher M. Haqq, Karim Fizazi. Exploratory Analysis of Survival Benefits and Prior Docetaxel Treatment in COU-AA-301, A Phase 3 Study of Abiraterone Acetate Plus LowDose Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Abstract #95325. Submitted to ASCO Annual Meeting. 1-5 June 2012 43. Robert Motzer, Camillo Porta, Georg A. Bjarnason, Cezary Szczylik, Sun Young Rha, Emilio Esteban, Ugo De Giorgi, Mary McKenzie, Paul Mainwaring, Scott North, Roberto Sabbatini, Istvan Bodrogi, Fairooz Kabbinavar, Giacomo Carteni, Cora N. Sternberg, Nicholoas Vogelzang, Michael Shi, Gladys Urbanowitz, Bernard Escudier. Phase III Trial of Dovitinib (TK1258) versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-Angiogenic (VEGF-Targeted and mTOR Inhibitor) Therapies. Abstract #96688 submitted to ASCO Annual Meeting. 1-5June 2012 44. P.Mainwaring (co-author). Interim Analysis Results of COU-AA-302, A Randomised, Phase III Study of Abiraterone Acetate in Chemotherapy Naïve Patients with Metastatic CastrationResistant Prostate Cancer (mCRPC). Abstract #95300 submitted to ASCO Annual Meeting. June 1-5 2012. 45. P. Mainwaring, (co-author). First-Line Use of Cabazitaxel in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Three-Arm Study in Comparison with Docetaxel. Abstract #96516 submitted to ASCO Annual Meeting June 1-5 2012. 46. Kim N. Chi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Robert J. Jones, John N. Staffurth, Scott North, Nicholas J. Vogelzang, Fred Saad, Paul Mainwaring, Stephen Harland, Jnr. Exploratory Analysis of Survival Benefit and Prior Docetaxel (D) Treatment in COU-AA-301. A Phase 3 Study of Abiraterone Acetate Plus Low-Dose Prednisone in Metastatic CastrationResistant Prostate Cancer (mCRPC).Citation: J. Clin Oncol 30, 2012 (suppl. 5; abstr 15) ASCO GU. San Francisco CA Feb. 2-4 2012. 47. Ethan Basch, Johann S. de Bono, Howard I. Scher, Arturo Molina, Cora N. Sternberg, Karim Fizazi, Scott A. North, Kim N. Chi, Robert J. Jones, Oscar B. Goodman, Paul N. Mainwaring, Amanda Farr, Margaret Rothman, Yanni Hao, Cameron S. Liu, Thian Kheoh, Chris M. Haqq, Eleni Efstathiou, Christopher Logothetis. Pain Control and Delay in Time to Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate: Long-Term Follow-Up. Citation: J. Clin. Oncol 30, 2012 (suppl 5; abstr 183) ASCO GU Poster. San Francisco CA Feb. 2-4 2012. 48. M.E. Gore, C. Porta, S. Bracarda, L. Crino, R. Hawkins, G. Bjarnason, S. Oudard, S. H. Lee, T. M. Kim, J. Yuan, K. Fly, C. Szczylik. Updated Safety and Efficacy Results for Sunitinib from a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma. ECCO/ESMO Sept. 2011 49. Cora N. Sternberg, Howard I. Scher, Arturo Molina, Scott North, Paul Mainwaring, Yanni Hao, Dennis Gagnon, Thian Kheoh, Chris M. Haqq, Johann S. de Bono. Fatigue Improvement/Reduction With Abiraterone In Patients With Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: Results From the COU-AA-301 Phase 3 Study. Poster Presentation. ECCO/ESMO Sept. 2011 50. C.N. Sternberg, H.I. Scher, A. Molina, S. North, P. Mainwaring, Y. Hao, D. Gagnon, C.M. Haqq, J.S. de Bono. Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-Docetaxel: Results from the COUAA-301 Phase 3 Study. ECCO/ESMO Sept. 2011.

27

Paul Mainwaring

51. Christopher J. Logothetis, Ethen M. Basch, Arturo Molina, Karim Fizazi, Scott A. North, Kim N. Chi, Robert J. Jones, Oscar B. Goodman, Paul N. Mainwaring, Cora N. Sternberg, Eleni Efstathiou, Dennis D. Gagnon, Margaret Rothman, Yanni Hao, Cameron S. Liu, Thian S. Kheoh, Effect of Abiraterone Acetate on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Docetaxel: Results of the COU-AA-301 Study. Presented as an Oral Presentation at ASCO 2011 Annual Meeting (June 3-7 Chicago IL). Abstract 4520. Submitted to Journal of Clinical Oncology Feb. 20 2012 C.N. Stemberg, H.I. Scher, A. Molina, S. North, P. Mainwaring, Y. Hao, D. Gagnon, T. Kheoh, C.M. Haqq, J.S. de Bono. Fatigue Improvement/Reduction with Abiraterone Acetate in Patients With Metastatic CastrationResistant Prostate Cancer (mCRPC) Post-Docetaxel: Results from the COU-AA-301 Phase 3 Study. April 18 2011. 52. C.N. Stemberg, H.I. Scher, A. Molina, S. North, P. Mainwaring, Y. Hao, D. Gagnon, T. Kheoh, C.M. Haqq, J.S. de Bono. Fatigue Improvement/Reduction with Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-Docetaxel: Results from the COU-AA-301 Phase 3 Study. April 18 2011. 53. A.C. Mita, R.S. Heist, O. Aren, P. Mainwaring, L. Bazhenova, S.M. Gadgeel, R.H. Blum, J. Polikoff, J. Biswas, M.A. Spear. Phase II Study of Docetaxel With or Without Plinabulin (NPI2358) in Patients with Non-Small Cell Lung Cancer (NSCLC). ASCO 2010 Annual Meeting. Abstract #7592. Citation:J Clin Oncol 28:15s, 2010 (suppl; abstr 7592). Category: Lung Cancer – Metastatic-Metastatic. Background: Plinabulin (NPI-2358) is a Vascular Disrupting Agent 9VDA That Acts on the Cytoskeleton to Destabilize Tumour Vascular Endothelial Cell Cohesion With Addition Cytotoxic Activity, Leading to Selective Tumour Vascular Disruption and Necrosis. 54. P. Mainwaring (added as a co-author). A Multicentre, Open-Label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects with Primary or Secondary Hepatic Tumour Burden. Abstract #51187. American Society of Clinical Oncology (ASCO). June 4-8 2010 55. P. Mainwaring (added as a co-author). Randomized Phase 3 Study of Panitumumab (pmab) with FOLFIRI vs FOLFIRI Alone as 2nd‑ Line Treatment (Tx) in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Analysis by Tumour Epidermal Growth Factor Receptor (EGFR) Staining. Abstract #53127. American Society of Clinical Oncology (ASCO). June 4-8 2010 56. P. Mainwaring (added as a co-author). Phase 2 Study of Docetaxel +/- Plinabulin (NPI-2358) in Patients with Non Small Cell Lung Cancer (NSCLC). Abstract #48380. American Society of Clinical Oncology (ASCO). June 4-8 2010. 57. C. Twelves, D. Loesch, J.L. Blum, L.T. Vahdat, K. Petrakova, P.J. Chollet, C.E. Akerele, S. Seegobin, J. Wanders, J. Cortes, on behalf of the Study 305 investigators.. A Phase II Study (EMBRACE) of Eribulin Mesylate versus Treatment of Physician’s Choice in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane. Abstract # CRA1004^. Sub-Category: Metastatic Breast Cancer. Category: Breast Cancer –Metastatic Breast Cancer. Citation: J Clin Oncol 28:18s,2010 (suppl; abstr CRA1004^). American Society of Clinical Oncology. (ASCO 2010) June 4-8 2010. 58. P.N Mainwaring, J. Lickliter, M.P. Brown, M. Millward, D.J. Chaplin, Z. Goldberg. A MultiCentre, Open-Label, Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden. ASCO 2010 Annual Meeting. Abstract #TPS164. Citation: j Clin Oncol 28:15s, 2010 (suppl; abstr TPS164). Category: Development Therapeutics – Clinical Pharmacology and Immunotherapy – Phase 1 Studies. Background: Combretastatin A1 diphosphate (CAIP, Oxi4503) is a Novel Vascular Disrupting Agent (VDA) that is a Reversible Tubulin-Binding Agent with Direct Cytotoxic Activity when Bioactivated to its Reactive Orthoquinone Metabolite.

28

Paul Mainwaring

59. M. Peeters, A. Cervantes-Ruiperez, A.Strickland, T.Ciuleanu, P.N. Mainwaring, V.I. Tzekova, A.Santoro, C.S.Johnson, A.Zhang, J.L.Gansert. Randomized Phase III Study of Panitumumab (pmab) with FOLFIRI versus FOLFIRI Alone as 2nd Line Treatment (tx) in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Analysis by Tumor Epidermal Growth Factor Receptor (EGFR) Staining. ASCO 2010 Annual Meeting. Abstract #3565^. Citation: J Clin Oncol 28:15s, 2010 (suppl; abstr 3565^. Category: Gastrointestinal (Colorectal) Cancer – Colorectal Cancer. Background: Pmab, A Fully Human, Anti-EGFR Monoclonal Antibody, plus FOLFIRI vs FOLFIRI was Evaluated as 2nd-line Tx for mCRC by Tumour KRAS Status; Efficacy Analyses by EGFR Staining Were Also Performed. Methods: Patients who received 1 prior chemotherapy 60. Peter Kaufman, Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Bob Sikorski, dusan Kotasek.. Phase 1b Study of Motesanib Diphosphate Plus Paclitaxel or Docetaxel for Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer: Interim Results. ESMO/ECCO 2009 61. S. Lee, HC Chung, P. Mainwaring, MH Toh, C. Ng, WC Chang, P. Kwong, R. Li, V. Sriuranpong, TC. Keong, SP Lowenthal.. An Asian Subpopulation Analysis of the Safety and Efficacy of Sunitinib in Metastatic Renal Cell Carcinoma. ECCO/ESMO 2009 62. Michael Millward, Paul Mainwaring, Matthew A. Spear, Monica Mita, Kristine Federico, G. Kenneth-Lloyd, Gillian Cropp, Alain Mita. The Novel Vascular Disrupting Agent (VDA) NPI2358 Combined With Docetaxel in Patients with NSCLC. IASLC. March 2009 and ASCO 2010. 63. Peter Kaufman, Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Bob Sikorski, dusan Kotasek.. Phase 1b Study of Motesanib Diphosphate Plus Paclitaxel or Docetaxel for Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer: Interim Results. SABCS 2008 and ESMO/ECCO 2009 64. Amanda Townsend, Michael Millward, Timothy Price, Paul Mainwaring, Andrew Spencer, Angie Longenecker, Michael A. Palladino, G. Kenneth Lloyd, Matthew A. Spear, Peeter Padrik. Clinical Trial of NPI-0052 in Advanced Malignancies Including Lymphoma and Leukemia (Advanced Malignancies Arm). Abstract American Society of Clinical Oncology (ASCO) June 2009. 65. Ahmad A. Tarhini, Michael Millward, Paul Mainwaring, Richard Kefford, Ted Logan, Anna Pavlick, Steven J Kathman, Kevin H. Laubscher, Mohammed M. Dar, and John M. Kirkwood. A Phase II, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma. 66. Mark McKeage, Michael Jameson, David Gibbs, Mark Rosental, Paul Mainwaring, Joachim von Pawl (for AS1404-201 Study Investigators). Abstract NZSO June 2008 67. P. Mainwaring.. A Phase 1a Safety and Pharmacokinetic Study of Oral NV-196 in Patients With Solid Tumours. ASCO June 2008 68. Amanda Townsend, Peeter Padrick, Paul Mainwaring, Timothy Price, Laurence Catley, Angie Longenecker, Michael A. Palladino, G. Kenneth Lloyd, Matthew A Speark, Michael Millward. Phase 1 Clinical Trial of the 2nd Generation Proteasome Inhibitor NPI-0052 in Patients With Advanced Malignancies With a CLLRP2D Cohort. NCI-EORTC May 2008. ASCO June 2009 69. Richard de Boer, Peter Kaufman, Shane White, Paul Mainwaring, Bogda Koczwara,Yining Ye, Yu-Nien Sun, Mandy Parson, Ada Braun, and Dusan Kotasek.. Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer With Motesanib Diphosphate Plus Paclitaxel or Docetaxel: Results From a Phase 1b Study. EBCC 2008 A 582 70. S. P. Ackland, S. Clarke, R. Perez-Carrión, S. Chiara, J. Gapski, P. Mainwaring, B. Langer, S. Young, A. Sobrero and colleagues. Updated Efficacy Data From Aviri, A Large Phase I Trial of First-Line Bevacizumab Plus Folfiri In Patients With Metastatic Colorectal Cancer. ASCO GI 2008 A463

29

Paul Mainwaring

71. Richard de Boer, Shane White, Paul Mainwaring, Bogda Koczwara, Yining Ye, Yu-Nien Sun, Mandy Parson, Ada Braun and Dusan Kotasek.. Safety and Pharmacokinetics of Motesanib Diphosphate (AMG 706) With Paclitaxel or Docetaxel for the Treatment of Locally Recurrent, Unresectable or Metastatic Breast Cancer. SABCS 2007 72. Martin E. Gore, Cezary Szczylik, Camillo Porta, George Bjarnason, Stephen Oudard, Subramanian Hariharan, Se-Hoon Lee, John Haanen, Dniel Castellano, Eduard Vrdoljak, Patrick Schoffski, Paul Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald Bukowski. Safety and Efficacy of Suninitib with Subpopulation Analysis in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma. 14th European Cancer Conference, September 23-27, 2007. Barcelona, Spain. 73. Martin E. Gore, Cezary Szczylik, Camillo Porta, George Bjarnason, Stephen Oudard, Subramanian Hariharan, Se-Hoon Lee, John Haanen, Dniel Castellano, Eduard Vrdoljak, Patrick Schoffski, Paul Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald Bukowski. Safety and Efficacy of Suninitib with Subpopulation Analysis in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma. 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) June 15, 2007, Chicago, IL 74. Sobrero, S. Ackland, S. Clarke, R. Perez-Carrión, S. Chiara, J. Gapski, P. Mainwaring, M. Balcewicz, B. Langer, S. Young. Final Data From A Large Phase IV Trial of First-Line Bevacizumab Plus Classic or Modified FOLFIRI in Metastatic Colorectal Cancer (CRC). Proc Ann Am Meet Soc Clin Oncol 2007 75. N Pavlakis, M Boyer, M Millward, P. Mainwaring, K Pittman, C Lewis, J Shapiro, R Abraham, F Abell, C Underhill, K Horwood, G Hawson, B.Creese and E.Wilson. Multi-Centre Randomised Phase II Trial of PI-88, a Novel Heparanase Inhibitor, With Weekly Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). World Lung Cancer Conference 2007 76. P.N. Mainwaring, Dr C. Shannon. A11068 PASCO 2007. A Phase II Study of Dose-Dense Chemotherapy {Doxorubicin (A), Cyclophosphamide (C), Paclitaxel (T), Gemcitabine (G)} Supported by Pegfilgrastim (P) and Darbepoetin-alfa (D) for Patients With High-Risk Early Stage Breast Cancer (ICANDO) 77. J. M. Kirkwood, R. Kefford, T. Logan, P. N. Mainwaring, M. Millward, A. C. Pavlick, M. M. Dar, S. Kathman, K. Laubscher, W. Bell. Phase II Trial of Iboctadekin (rhIL-18) on a Daily X 5 Schedule in Metastatic Melanoma (MM). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 10043 78. B. Sizer, A. Makris, C. Barone, P. Mainwaring, P. Eggleton. QoL and Resource Use Analysis of Tegafur-Uracil/LV or 5-FU/LV in First-Line Metastatic Colorectal Cancer (mCRC): Final Results of a Multi-Center Phase II Study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3631 79. A. Pluzanska, P. Mainwaring, J. Cassidy, B. Utracka-Hutka, J. Zalucki, R. Glynne-Jones, P. Koralewski, J. Bridgewater, H. Wasan, D. Cunningham. Final Results of A Randomized Phase III Study Evaluating the Addition of Oxaliplatin First-Line to 5-FU Followed by Irinotecan at Progression in Advanced Colorectal Cancer (LIFE study). Proc Annu Meet Am Soc Clin Oncol 2005 A: 3517 80. S. Vukelja, J. O'Shaughnessy, S. Campos, L. Vahdat, J. Blum, D. Yardley, P. Mainwaring, F. Senecal, R. Benner, L. Denis, E. Perez. Activity of Oral Irinotecan (IRI) in Metastatic Breast Cancer (MBC) Patients After Prior Anthracycline, Taxane and Capecitabine: Phase 2 Study Results. Proc Annu Meet Am Soc Clin Oncol 2005 A562 81. R. Prue, T. Rosetti, S. Fitzpatrick, R. Wilkinson, K. Radford, P. Swindle, P. Mainwaring, D. N. Hart. A Phase I Clinical Trial of a BDCA-1+ Blood Dendritic Cell Preparation Loaded With Control and Tumour-Associated Antigens, for Immune Therapy of Metastatic Refractory Prostate Cancer. Proc Annu Meet Am Soc Clin Oncol 2005 A2599

30

Paul Mainwaring

82. Barone C, Sizer B, Mainwaring PN, Steger G,et al. Randomized Study of Oral UFT (Uracil/Ftorafur) plus Leucovorin (LV) or Parenteral 5-FU/LV in Patients With Metastatic Colorectal Cancer. Fourth International Conference on Colorectal Cancer, Barcelona, A33, 2002 83. N.G. Mikhaeel, P. Mainwaring, T. Nunan, A.T. Timothy. Prognostic Value of Interim and PostTreatment FDG-PET Scanning in Hodgkin Lymphoma. Guy's & St. Thomas' Cancer Centre & Clinical PET Centre, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. VIII International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2002. 84. J. Cassidy, D. Cunningham, B. Utracka-Hutka, J. Zaluski, R. Glynne-Jones, P. Mainwaring, P. Koralewski, J. Carmichael, L. Mounedji-Boudiaf, A. Pluzanska; Aberdeen Royal Infirmary, Aberdeen, UK; Royal Marsden Hospital, London, UK; Centrum Onkologii Wybrzeze, Gliwice, Poland; Wielkolpolskie Centrum Onkologii, Poznan, Poland; Mount Vernon Hospital, London, UK; St Thomas Hospital, London, UK; Oddzial Chemioterapii Szpital, Krakow, Poland; Nottingham City Hospital, Nottingham, UK; Sanofi-Synthelabo, Paris, France; Szpital Akademii Medycznej, Lodz, Poland. Oxaliplatin (Oxa)/5-FU/LV in First-Line Metastatic Colorectal Cancer Followed by Irinotecan: Interim Results of the Life Study., Proc Annu Am Meet Soc Clin Oncol, 21, A 1064 85. Paul N Mainwaring, Eric Van Cutsem, Jean-Luc Van Laethem, David Propper, Christopher Twelves, John Bridgewater, Bruno Audhuy, James Carmichael, Cornelis Punt, Jim Cassidy, Nicholas Stuart, Miroslav Ravic, St Thomas Hospital, London, UK; University Hospital Gasthuisberg, Leuven, Belgium; Erasme University Hospital, Brussels, Belgium; St Bartholomews Hospital, London, UK; Western Infirmary, Glasgow, UK; University College Hospital, London, UK; Hopital Pasteur, Colmar, France; City Hospital, Nottingham, UK; University Medical Centre, Nymegen, Netherlands; Institute of Medical Science, Aberdeen, UK; Ysbyty Gwynedd Hospital, Bangor, UK; Eisai Ltd, London, UK. A Multi-Centre Randomised Phase II Study of E7070 in Patients With Colorectal Cancer Who Have Failed 5-Fluorouracil-Based Chemotherapy. Proc Annu Am Meet Soc Clin Oncol 20, A611 86. Seynaeve C, Hough RE, Mainwaring PN, Judson I, Verweij J, Lorigan P. Consolidation High Dose Chemotherapy (HDCT) in Adult Patients With Small Round Blue Cell Tumours (SRBCT), Proc Annu Am Meet Soc Clin Oncol 19, A2214, 2000 87. Mainwaring PN, Cunningham D, Gregory W, Linch D, Hoskin P, Hancock B, Vaughan, Hudson

G. Mitozantrone Should Replace Doxorubicin In Patients Over 60 Years Of Age Receiving A Modification Of The PACEBOM Regimen. Results Of A BNLI Randomised Study Of PAdriaCEBO Vs. PMitCEBO In Patients With High-Grade Lymphoma. Eur Winter Oncol Meet 1999 88. Mainwaring PN, Horton C, Powles R, Treleaven J, Role of Autologous Transplantation in Patients with Multiple Myeloma (MM) aged 65 Years and Over. American Society of Haematology A 2731 Blood A 2731 1998 89. Mainwaring PN., Ellis, PA., Detre S, Smith IE, Powles TJ, Dowsett M. Comparison Of Alternative Methods To Assess Apoptosis In Breast Cancer Patients. ASCO A1971 1997 90. Dowsett M., Detre S., Ormerod M, Mainwaring PN., Ellis PA., Titley J., Smith IE. Apoptotic Cell Sorting and Analysis in Fine Needle Aspirates (FNAs) from Primary Human Breast Carcinomas (Bcs). AACR 1997; 38: 1589 91. Mainwaring PN., Ellis PE., Salter J., Anderson E., Howell A., Nicholson RI., Robertson JF., Smith IE., Reed J., Dowsett, M. Immunohistochemical Expression of BCL-2 and BAX is Unaffected by the Pure Antioestrogen ICI 182,780 in Human Breast Cancer. AACR 1997 38: 767 92. Mainwaring PN, Salter J, Johnston SD, Ellis PA, Smith IE, Ebbs SR, Dowsett M. Changes in Molecular Phenotype of Human Breast Carcinomas Associated with Tamoxifen Resistance. San Antonio Breast Cancer Symposium 1996 A 1567

31

Paul Mainwaring

93. Gore ME., Mainwaring PN., Macfarlane V., A'Hern R., Osborne R., Harper P., Quigley M., Slevin M., Jones A., Mansi J. Blake P. A Randomised Study of High versus Standard Dose Carboplatin in Patients (pts) With Advanced Epithelial Ovarian Cancer (EOC). NCI/EORTC New Drugs Meeting 1995. ASCO 1996 15; 284 A769 94. Mainwaring PN., Atkinson H., Chang J., Moore J., Hancock BW., Guillou PJ., Oskam R., Gore ME. High Differential Response Rate in Patients with Metastatic Malignant Melanoma Treated by Biochemotherapy. NCI/EORTC New Drugs Meeting 1995

32

Paul Mainwaring

Oral Presentations Mainwaring, P.N. Gore, M.E. Differential responses to chemoimmunotherapy in patients with metastatic melanoma. U.K. Melanoma Study Group, Southampton, 1996 Mainwaring P.N., A’Hern R.P., Macfarlane V., Slevin, M. Harper P., Osborne R., Quigley M., Jones A., Mansi J., Blake P., Wiltshaw E., Gore M.E. for the London Gynaecological Oncology Group. A randomised trial of dose intensity in advanced epithelial ovarian cancer (EOC). Br J Cancer 1997; 76: Suppl 1 50 1997 Mainwaring, PN, FY Ahmed, DM King, RP A’Hern, M Ramsden, B McLaren, J Mansi, P Harper, M Slevin, H Thomas, ME Gore for The LGOG A phase II study of epirubicin, cisplatin and prolonged venous infusional 5-FU (ECF) in relapsed epithelial ovarian cancer (EOC). Br J Cancer 1997; 76: Suppl 1 O51 1997

33

Paul Mainwaring

Talks and Presentations DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2016 Co-chair of Symposium 5: Role of Cytotoxic Chemotherapy in the Era of Personalised Medicine

28th – 30th April 2016

The Shilla Jeju Hotel Jeju Island, Korea

Global Breast Cancer Conference

20th April 2016

AIBN (Australian Institute for Bioengineering and Nanotechnology) St. Lucia, Brisbane

YPO (Young Presidents Organisation)

Personalized Vaccines for Cancer “Cure” 2016-2017

3rd – 6th March 2016

Kyoto International Community House and Westin Miyako Hotel, Japan

Combined Meetings of: • Kyoto Breast Cancer Conference • Asian Oncology Summit • Organisation for Oncology and Translational Research • Kyoto Breast Cancer Research Network

Can We Make Precision Medicine More Precise?

27th – 28th February 2016

Shangri-La Singapore

Asia Pacific Cancer Summit

Prognostic Models for Early Stage Breast Cancer: Latest Updates from SABCS 2015

23rd – 24th January 2016

Sofitel Macau at Ponte 16. Macau, China

•

Hyatt Regency Kong, China

•

15th – 16th January 2016

Hotel,

Hong

Haeundai Grand Hotel Busan, Korea

Breast

Monthly Meeting of Macau Urological Society Annual Scientific Meeting of Hong Kong Society of Uro-Oncology

Asia Pacific Urology Consortium 2016

•

•

Guidance from Clinical Practice on Prostate Cancer Management Androgen Receptor Blockers – Are They the Same?

Clinical Expert. Plenary Session 3: Modern Imaging in Prostate Cancer – Guidance from Clinical Practice

34

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2015 17th – 18th December

Brisbane Convention and Exhibition Centre

Brisbane Conference

Cancer Session: 17th Dec. Immunotherapy: Translation of Science Into Clinical Care. Topic: The Science, The Clinic Session: 18th Dec. Topic: Novel Systemic Therapies for GU Cancer

15th – 17th November 2015

Hong Kong

Astellas Speaker Tour

7th – 8th November 2015

Hyatt Regency Shantin, Hong Kong China

Biennial Chinese Topic: To Be Advised University Hong Kong Breast Cancer Conference.

Intercontinental Hotel Dubai

UAE Cancer Congress 2015

Uro-Oncology Session. Topic: To Be Advised

23rd – 24th October 2015

Shanghai China

10th Shanghai International Breast Cancer Symposium

Advances in Clinical Research of CDK Inhibitor in Breast Cancer

4th October 2015

The Outrigger Hastings Street Noosa QLD

USANZ Northern Topic: To Be Advised Section Meeting of Australasian Urological Society Oncological Management of Renal Carcinoma Conference.

29th – 31st October 2015

1. Recent Develoments in the Management of CRPC: Unmet Needs and Emerging Landscape 2. Overview of Enzlutamide – Experience and Moderated Discussion

35

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2015 (cont.) 2nd October 2015

9th – 11th September 2015

Singapore

Inaugural Joint Breast Topic: To Be Advised Cancer Symposium

The Novotel Brisbane

Australasian Neuroscience Nurses Association Conference.

New Molecular Pathology of Gliomas, Implications for Future Treatments

1st September 2015 Gambro Restaurant Function Centre 33 Caxton Street Petrie Terrace Brisbane

3st July – 1st August 2015

&

Novartis Chair for guest speaker: International Renal Dr Emiliano Calvo Cancer Meeting Topic: Making Choices in mRCC: Optimizing Patient Outcomes with Different Treatment Options Best of ASCO – 1st 1. The ABCS of ImmunoSSO Annual Scientific Oncology Meeting 2. TROG 03.06 andVCOG PR 01-03: The “Timing of Androgen Deprivation Therapy in Prostate Cancer Patients with a Rising PS (TOAD)” Collaborative Randomised Phase III Trial.

25th July 2015 Mandarin Oriental Macau, China

Organisation for CDK 4/6 Inhibition Oncology Translational Research. (OOTR) Breast Cancer Scientific Symposium

36

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

2015 (cont.) 3rd – 5th July 2015

29th May – 2nd June 2015.

2nd May 2015

1st May 2015.

Hotel Chinzanso Tokyo, Japan

McCormick Place, Chicago, Illinois. USA

CONFERENCE/ MEETING

TOPIC

Session Title Emerging Perspectives in 4th ACE Prostate Prostate Cancer (EPiC) Cancer Conference 1. Molecular Paradigms in CRPC (Speaker) Debate: Current Opinions in Prostate Cancer (Moderator) 2. Use of Biomarkers in CRPC and Future Treatment in Asia (Speaker) Poster Presentation: ASCO (American Multi-platform Quality Society for Clinic Assurance (QA) comparison Oncology). of Next-Generation Sequencing (NGS) technologies incorporating bespoke simultaneous copy number variation (CNV) reporting

Intercontinental Melbourne the Rialto

PCPA (Private Physicians Australia)

Park Royal Hotel Melbourne Airport

Astellas Meeting

Cancer of

Board

37

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

2015 (cont.) 11th – 12th April 2015

Adelaide Convention Centre, Adelaide, South Australia

CONFERENCE/ MEETING

TOPIC

Poster Presentation: USANZ 68th Annual Scientific Meeting 1. Early Access Protocol (EAP) with Abiraterone Acetate (AA) for Patients in the Asia-Pacific Region with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Progressing After Chemotherapy. 2. SPARTAN – A Randomised DoubleBlind Comparative Study of ARN-509 plus Androgen Deprivation Therapy (ADT) vs ADT Alone in Non-Metastatic Castration-Resistant Prostate Cancer (MOCRPC).

10th – 12th April 2015 Shanghai International Convention Center Shanghai, China

OOTR (Organisation Oncology Translational Research)

Hilton Hotel, Brisbane

4th Asia Pacific Breast Opening Ceremony Address Cancer Summit. And Chair of Sessions

Hilton Hotel, Brisbane

HER2 Innovations: Co-Chairperson and Panel Expert Masterclass Discussion Member

27th – 28th March 2015

27th March 2015

for and

1. Immune Signatures and Clinical Outcome in Breast Cancer. 2. Co-Chair of session. 3. The Tumour Microenvironment. (Led by OOTR) Combination or Stand Alone? How To Best Use Immunotherapies

38

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2015 (cont.) Sofitel. Broadbeach

ANZGOG 2015

24th March 2015

Brisbane

Colorectal Meeting

24th – 25th March 2015

Jeju, South Korea

ABC Networking 1. Tumour Registry Business Meeting. 2. Mentorship Program

25th - 26th March 2015

Investigation of the Integrated Genomics to Determine Prognosis and Likely Response to Treatment.

Surgeons Adding “Omics” to ColoRectal Cancer Management.

Global Breast Cancer 1. Molecular Genomics of Conference 2015 & 4th Breast Cancer International Breast 2. Targeted Molecular Cancer Symposium Therapy of Breast Cancer 3. Immunotherapy of Breast Cancer

7th March 2015

UQ Centre, University of Queensland. Brisbane

Men’s Health Seminar

1st March 2015

Southern Cross Sports Club. Upper Mt Gravatt. Brisbane

Triple Negative Breast Cancer Awareness Group - Luncheon

Brisbane Convention and Exhibition Centre

Brisbane Conference

New Developments in Treating Prostate Cancer.

2014 18th – 19th December 2014

Session: Cancer Lectures Celebrating Cancer Research Success In Brisbane. Topic: Prostate Cancer

39

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2014 (cont.) 16th October 2014

Brisbane Centre

Convention

19th September 2014 Xiamen, China Xiamen International Conference Centre Hotel

Australian Lung Impact of COPD on Lung Cancer Conference Cancer Diagnosis and Treatment. Organisation of Immunotherapy in Breast Oncology and Cancer: For Whom, When, Translational Research Where and Why? In conjunction with 17th Annual Meeting of Chinese Society of Clinical Oncology

22nd August 2014

Tokyo – Japan

Janssen. What We Have Learnt From Asia Pacific Prostate AUA/ASCO 2014? Cancer Virtual Symposium

17th – 19th July 2014

Hanoi –Vietnam

Roche – Breast Cancer HER2 (+) Breast Cancer Management Meeting Management – New Tools – New Strategy

Ho Chi Minh City – Vietnam

Roche – Breast Cancer HER2 (+) Breast Cancer Management Meeting Management – New Tools – New Strategy

Taipei - Taiwan

Janssen – Zytiga Androgen Biosynthesis Symposium – W Hotel Inhibitors: Clinical Data and Practical Management in Taiwan Urological Castrastion-Resistant Oncology Association Prostate Cancer. Annual Congress

The Sheraton Hotel Noosa

PCPA Comprehensive Molecular (Private Cancer Analysis Through A New Physicians of Clinic Trial Australia) 2014 Annual Scientific Meeting

30th – 31st May 2014

21st – 23rd March 2014

40

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2014 (cont.) Brisbane Convention and Exhibition Centre

Janssen Meeting

Brisbane Convention and Exhibition Centre

67th USANZ Meeting Abstract Presentation: (Urological Society of Australia and New Association of Alkaline Zealand) Phosphatase With Clinical Outcomes in ChemotherapyNaїve Patients With Metastatic CastrationResistant Prostate Cancer: Results from COU-AA-302

Hilton Hotel Surfers Paradise Gold Coast

ICON Weekend

28th February – 2nd March 2014

Grand Hyatt Hotel Melbourne

12th Annual HOTT Meeting

22nd – 23rd February 2014

Shangri-La Singapore

3rd Asia-Pacific Breast Why Should We Care About Cancer Summit the Immune System and Breast Cancer?

Vietnam

Roche - Vietnam

th

18 March 2014

16th – 19th March 2014

Breakfast Improving Patient Outcomes in Metastatic Advanced Prostate Cancer

15th – 16th March 2014 Clinical Comprehensive Molecular Analysis Through A New Clinic Trial Member of HOTT Steering Committee

2013 21st December 2013

•

Ho Chi Minh City •

The Role of Trastuzumb in HER2(+) in Breast Cancer Mangement. The Latest Updates that Change Clinical Practice from SABCS 2013.

41

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2013 (cont.) th

10 – 14 2013

th

December

Henry B. Gonzalez Convention Center, San Antonio, Texas USA

2nd December 2013

29th – 30th November 2013

San Antonio Breast Abstract Presentation: Cancer Symposium Quality Metric Study of Real-Time Targeted Massive Parallel Sequencing (MPS) Ampliseq Comprehensive Cancer Panel (CCP) and Bioinformatics in Early Breast Cancer (EBC) Using Life Technologies Ion Proton System. Mater Private Hospital Recent Trends in the Neurosciences – Treatment of Glioblastoma Thinking Ahead – Multiforme. Advanced Clinical Practice

Vietnam

Janssen Oncology • Masterclass

Hanoi 29th November Ho Chi Minh City 30th November

•

19th September 2013

Sunshine Coast

Sunshine Prostate Meeting

22nd – 26th August 2013

Singapore

Janssen Speaking Tour

Brunei

Emerging Therapy for Metastatic CastrateResistant Prostate Cancer – An introduction of Zytiga in Post Chemotherapy Setting. Case Presentation – An Australian Experience. Zytiga in Patients with Metastatic CastrateResistant Prostate Cancer After Docetaxel Failure.

Coast New Strategic Directions in Cancer Advanced Prostate Cancer.

COU-AA-302 Updates (Opiate Use, Time to Chemotherpay, Quality of Life Issues…… • Steroid Use – Clinical Implications in the Context of Abiraterone Acetate. Case Discussion – Abiraterone Acetate in Chemotherapy Naїve Patients. •

42

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2013 (cont.) Ipswich Club

Peter Dunne

Personalised Medicine – An Emerging Reality.

30th July 2013

Souths League Club Function Room, Davies Park, West End

Triple Negative Breast Cancer Awareness Group – Australia

Triple-Negative Breast Cancer 2013.

16th July 2013

Runcorn Tavern

Brisbane Macgregor Lions Club Meeting

Personalised medicine new technology 201.

14th July 2013

Gold Coast Centre

ANZUP Trainee Day

Renal Cancer Panel – Trainee Teaching Session. Renal Cell Carcinoma – Multiple/Bilateral Tumours & Hereditary Syndromes.

14th – 16th May 2013

The Park Lane Hotel and Hong Kong Sanatorium Hospital Hong Kong

Janssen Tour

Optimizing Treatment Outcomes in Metastatic Castration Resistant Prostate Cancer. • CRPC Biology • Abiraterone MOA • Latest Clinical Results from EAU, AUA Case studies sharing from 302

15th August 2013

Convention

–

Speaking

Macau

12th – 14th April 2013

Shangri-La Kuala Lumpur

2nd Asia-Pacific Breast Cancer Summit

and

New Approaches to Neoadjuvant Therapy for Luminal Breast Cancer Panelist for Expert Case Challenges and Panel Discussion • Overcoming Resistance to anti-HER2 Therapy: Is A Combination Strategy the Key? Panelist for case discussion: A Journey Through Hormone Receptor Positive Breast Cancer: From Adjuvant to Metastatic Molecular Profiling 101: What the Practicing Medical Oncologist Surgeon and Radiation Oncologist Needs to Know. •

43

Paul Mainwaring

Talks and Presentations (cont.) DATE PLACE

CONFERENCE/ MEETING

TOPIC

2012 Saujana Hotel Kuala Lumpur

Janssen – Joint Evolving Treatment Options Malaysian-Scottish with Metastatic CastrationUrological Conference Resistant Prostate Cancer. 2012 Dinner Symposium

Edsa-Shangri-La Hotel. Mandaluyong City, Manila, Philppines.

Janssen – Medical Oncologists and Urologists Meeting

3rd November 2012

Jogjakarta Indonesia

Novartis: The Annual mTOR Pathways in Breast Meeting of Surgical Cancer and Update on Oncologists BOLERO Study.

21st October 2012

Daegu - Korea

Roche Korea Breast Key Questions in the Cancer Forum Treatment of Breast Cancer

20th October 2012

Daegu - Korea

Roche Korea Breast Current and Future Cancer Forum Perspective of HER2 Positive Breast Cancer.

Hilton Kuala Lumpur

Scenario of Malaysia’s mCRPC 1. Current Prostate Cancer and Abiraterone Management (Prevelence, Advisory Board Diagnosis, Patients’ Meeting. Stratifications, Treatment Landscape) and Unmet Needs inLocal Treatment Algorithm. (Australian Perspective). 2. Abiraterone Acetate’s Role in Local mCRPC Treatment Algorithm and Date/Educational Gaps Identification. (Sharing on forthcoming Tx options and chemo-naїve pt pools – pivotal clinical data, ongoing trials and upcoming indications). 3. mCRPC Management: Data Generation Opportunities & Medical Education Needs.

nd

22 November 2012

st

21 November 2012

Bridging the Gaps in the Management of Prostate Cancer.

11th August 2012

44

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2012 (cont.) 11th August 2012

Hilton Kuala Lumpur

Scenario of Malaysia’s mCRPC 4. Current Prostate Cancer and Abiraterone Management (Prevelence, Advisory Board Diagnosis, Patients’ Meeting. Stratifications, Treatment Landscape) and Unmet Needs inLocal Treatment Algorithm. (Australian Perspective). 5. Abiraterone Acetate’s Role in Local mCRPC Treatment Algorithm and Date/Educational Gaps Identification. (Sharing on forthcoming Tx options and chemo-naїve pt pools – pivotal clinical data, ongoing trials and upcoming indications). 6. mCRPC Management: Data Generation Opportunities & Medical Education Needs.

5th – 6th May 2012

Crowne Hotel, Victoria

Novartis Meeting

30th April 2012

Janssen Head Office Macquarie Park Sydney

Global Oncology Meeting

San Antonio, Texas

CTRC-AACR San Treatment of Metastatic Antonio Breast Cancer Breast Cancer: Breast Cancer Conference. CME As A Chronic Disease. (Moderator).

Promenade Melbourne,

R

&

D

Challenges and Implications of Assessing Multi-targeted Approaches in Clinical Trials.

Janssen mCRPC and Abiraterone. R & D

2011 6th - 10th December 2011

45

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2011 (cont.) 2nd – 4th November 2011

Hong Kong

Abiraterone Current Advance of Prostate Investigator Meeting. Cancer Treatment. 2nd Nov. Side effect management and efficacy relating to the Abiraterone Clinical Trial. Hong Kong Society of Current Advance of Prostate Clinical Oncology. Cancer Treatment. Where Lecture to Medical Are We Now. Oncologists. 3rd Nov. Urology Symposium 2011. 4th 5th Nov.

2nd – 3rd September 2011

Singapore

Elsevier Best of ASCO 2011

Updates on Management of CRPC. 1. “BRIM 2: An open-label, multicentre phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. 2. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for four weeks induction only in patients with intermediate and high Risk melanoma (Intergroup trial E1697) 3. A phase III randomized study of ipilimumab plus dacarbazine versus dacarbazine alone in first line treatment in patients with unresectable stage III or IV melanoma. Phase III randomized, openlabel multicentre trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E mutated melanomas.

46

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

Pfizer Smoke Signals – Preventative Disease, A Treatable Cause

Title: The Carcinogicity of Smoking. Presentation Summary: It is well known that smoking is a risk factor to specific cancers. This session will evaluate the key oncogenic differences between a smling and nonsmoking patient in General Practice, from screening through to treatment.

2011 (cont.) 30th August 2011

Brisbane

Workshop Format: Who to screen and when?: Reviewing guidelines, review the group’s current practice in who they evaluate for cancers and when. 4. 3rd – 5th March 2011

Yangon Myanmar

Roche Advancing the Treatment for Regional Oncology Patients with HER2 Positive and Haematology Early Breast Cancer. Meeting Herceptin: Defining the Optimal Duration of Treatment.

8th February 2011

Brisbane

Colorectal Cancer Journal Club

Future Strategies Cancer.

for

Management Colorectal

2010 6th – 8th August 2010

? Prostate Foundation Australia

Presentation 6th Aug.

Cancer New Treatment for of Advanced Prostate Cancer – Here and Now.

2009 16th – 18th October 2009

Byron Bay

Urological Society Queensland

Novel Evolving Role of Chemotherapy Agents in Prostatic Cancer. Abiraterone and Medivation.

47

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2009 (cont.) India

Symposium

Afinitor.

1st – 2nd October 2009

Philippines

Roche Launch of Avastin and Docetaxel Indication

Breast Cancer Particularly in the Metastatic Setting.

25th August 2009

Brisbane

Mater Medical Research Institute

What’s New In Oncology?

4th April 2009

Korea

The Korean Urological Oncology Society (KUOS)

Expanded Clinical Experiences of TKI’s and Novel Agent for Metastatic Renal Cell Carcinoma.

th

10 – 11 2009

th

October

LECTURE CONTENT: 1. TKI New Data 2. Introduction of Mtor Inhibitors Temsirolimus and Everolimus. March 2009

CME on Breast Cancer Australia. Podcast

Optomising Patient Treatment After Progression on Trastuzumab.

Changing Oncology.

2008 ? 2008

Brisbane

Mater Medical Research Institute – Annual Meeting

28th October 2008

Brisbane

Breast Cancer Breakfast

26th August 2008

Brisbane

KRAS Pathology Dinner – Queensland

August 2008

Melbourne

Landscape

In

The Erbitux Clinical KRAS Data. ESA’s and Cancer – A Double Edged Sword.

48

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2008 (cont.) 21st July 2008

Broadbeach (Gold Coast)

Urology Meeting

Urological Cancer Update 2008.

19th – 20th July 2008

Taiwan

Tykerb Launch Symposium – (a New Horizon for ErbB2 Driven Breast Cancer)

1. Optimizing Patient Treatment after Progression on Trastuzumab. 2. Options for First Line Treatment for ErbB2 Positive Breast Cancer.

20th – 22nd June

Melbourne

Asia Pacific Forum of Nephrology

EPO In Oncology.

2nd September 2007

Korea (Seoul)

Asia Pacific Japan Lung Cancer Advisory Board

Predictive Markers for Cytotoxics in Lung Cancer.

April 11th 2007

?

?

Triple Negative Breast Cancer: The Race is On……

14th – 15th April 2007

Thailand (Bangkok)

Asia Pacific Breast Cancer Regional Medical Conference

Brisbane

Mater Foundation/Stocklands Apartment Launch

21st June 2008 2007

Interactive Cases 1st Line Prior Taxane.

2006 19th October 2006

Chocking the Death Out of Cancer.

49

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

7th International Conference of the Asian Clinical Oncology Society in Conjunction with 9th Annual Meeting of Chinese Society of Clinical Oncology

Evolving Standard Approach as Breast Cancer Adjuvant Therapy.

2006 (cont.) 12th – 18th September 2006

China

13th September 2006

Shanghai

16th September 2006

Beijing

Evolving Standard Approach as Breast Cancer Adjuvant Therapy. Lecture at BMS Satellite Symposium of ACOS meeting on topic: The Evolution of Tubulin Agents for Cancer Therapy.

9th – 12th August 2006

Gold Coast (Sanctuary Cove)

MOGA - Annual Scientific Meeting

Angiogenisis Inhibitors.

14th June 2006

Brisbane

Sister Angela Appeal

Mary

Beginning of Research at the Mater.

3rd – 7th May 2006

Hamilton Island

Australian Society of Gynaecologic Oncologists (ASGO)

Directions in Clinical Studies for Advanced Ovarian Cancer: Preclinical Evidence.

18th January 2006

Gold Coast (Broadbeach)

Pfizer Australia Sales Conference

Brisbane

Australian Gastroenterology Week

2005. 19th – 22nd October 2005

Anti-angiogenic Factors for Cancers: Potential Therapeutic Avenues.

50

Paul Mainwaring

Talks and Presentations (cont.) DATE

PLACE

CONFERENCE/ MEETING

TOPIC

2005 (cont). 14th - 18th October 2005 14th October

Asia

Speaker Tour in Asia

Vietnam

1. The Genomic Sutdy of Breast Cancer: Using DNA Microarrays. 2. The Evolution of Tubulin Agents for Cancer Therapy. Clinical Approaches in the Treatment of Breast Cancer.

Thailand

Thai Medical Oncology Annual Meeting – Thailand

17th October

Philippines

18th October

Philippines College of Physicians

China

23 – 24h July 2005

Sydney

GI Pfizer Forum

26th – 28th January 2005

Florida (Miami)

GI Cancer Symposium and Thought Leader Program

Sydney

Roche Colorectal Cancer Focus Group

Anti-VEGF: A Unique Mechanism for Targeting CRC.

16th June 2004

Brisbane Conrad Hotel

Post ASCO meeting

Presentation from ASCO.

25th May 2004

Canberra

Presentation for SanofiAventis

7th – 8th May 2004

Spain (Madrid)

15th October

Oncology

Chair of Session.

2004 16th July 2004

NeoRecormon Event

Sydney

Updates

Own

Energising Anaemia Management for Patients with Cancer 19th – 23rd March 2004

on

Pfizer Oncology Forum

Anaemia Tomorrow: CERA.

Management The Role of

Interactive Debate: Should Camptosar (Irinotecan) in Combination Therapy Be Offered as the First Line Treatment Option in Patients with Metastatic Colorectal Cancer?

51

Paul Mainwaring

Talks and Presentations (cont.) Other Local Talks and Presentations to: GP’s

Brisbane Ipswich Gladstone Townsville

Other consultant groups in Brisbane: Breast Cancer Surgeons and Groups Colorectal Surgeons Urologists Other Consultant groups Overseas: Medical Oncologists Urologists Breast Cancer Groups at Mater Private Hospital and Ipswich Hospital ICON Cancer Care Medical and Nursing Staff - Brisbane Numerous Advisory Board, Steering Committee and Investigator Meetings both within Australia and overseas with regards to clinical trials and new molecules/drugs

52